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Allogeneic hematopoietic stem cell transplantation (allo-HCT) is an effective 
means by which to treat a wide variety of diseases resulting from dysfunctional 
hematopoiesis due to a potent anti-tumor response known as the graft-versus-
tumor (GVT) effect after chemotherapy and/or irradiation. The necessity of donor 
T cells to mediate GVT is offset by the consequential development of graft-
versus-host disease (GVHD); a leading cause of mortality among allo- HCT 
recipients. The IL-12 family of cytokines signals through Janus Kinase 2 (JAK2) 
and is comprised of IL-12, IL-23, IL-27, IL-35 and IL-39. IL-12 (p35+p40) and IL-
23 (p19+p40) have well documented proinflammatory functions responsible for 
Th1 differentiation and Th17 stabilization, respectively, and play critical roles in 
GVHD development. As such, we found that targeting p40 resulted in reduced 
GVHD. IL-12R and IL-23R also share a β-chain, IL-12Rβ1. While IL-23R is 
widely implicated in autoimmunity and GVHD, the role of IL-12Rβ1 remains much 
less defined. We found that donor splenocytes deficient for IL-12Rβ1 or IL-23R 
had an impaired ability to induce chronic GVHD (cGVHD). We also found a 
pathogenic role for IL-23R on donor T cells in acute GVHD (aGVHD); strikingly, a 
similar effect was not seen for IL-12Rβ1. Our studies then focused on 
determining how pharmacologically targeting IL-12/23p40 can be efficacious in 
reducing GVHD severity in experimental and clinical settings, yet also to explain 
why IL-12Rβ1 may be dispensable in aGVHD. The newest member of the IL-12 
family, IL-39, is composed of IL-23p19 and EBI3. Given the cognate receptor for 
IL-39 includes IL-23R and gp130, we hypothesized that IL-39 may play a role in 
 vi 
aGVHD. We detected significantly higher IL-39 in serum of mice with aGVHD 
compared to recipients of bone marrow alone (BMA) and cGVHD, providing a 
potential explanation for how IL-23R signaling could bypass IL-12β1. We also 
evaluated how JAK2 impacted GVHD. We found that T cell deficiency of JAK2 or 
neutralization via pacritinib significantly reduced mortality from GVHD. In 
summary, targeting IL-12 family signaling is an effective strategy to reduce 
GVHD. Further, future studies should focus on whether targeting IL-23/IL-39p19 






















I.1. Allogeneic Hematopoietic Stem Cell Transplantation 
The use of the atomic bomb in World War II not only revolutionized warfare but 
also the methods to treat bone marrow aplasia caused by radiation damage. In 
1950, it was found that syngeneic bone marrow transplantation (BMT) could 
effectively compensate for bone marrow dysfunction resulting from irradiation 
using murine models1. By 1956, this concept of replacing dysfunctional bone 
marrow was applied to murine models of leukemia and consequential aplasia 
following irradiation. This study involved two groups of mice: one that received a 
syngeneic (genetically identical) BMT and the other that received an allogeneic 
(genetically disparate) BMT. While aplasia was effectively treated in both groups, 
all mice that received a syngeneic transplant succumbed to leukemia relapse. 
However, the group of mice that received an allogeneic BMT (allo-BMT) did not 
experience any sign of disease relapse, but instead died from a “wasting disease”, 
which would later manifest into what is currently known as Graft-versus-Host 
disease (GVHD)2. The aforementioned experiments led to two major discoveries 
which catalyzed the birth of immunology: the identification and typing of human 
leukocyte antigens (HLA), as well as the ability of a genetically mismatched 
immune system to eradicate tumor cells3–5. In 1990, the Nobel Prize was awarded 
to E. Donnall Thomas for his unrelenting pursuit and discoveries regarding allo-
BMT as a therapy for cancer. 
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Today, allogeneic hematopoietic cell transplantation (allo-HCT) is performed with 
curative intent for high-risk blood cancers and bone marrow failure syndromes. 
The efficacy of allo-HCT lies in the ability of the donor graft to mediate a potent 
anti-tumor response in transplant recipients, known as the graft-versus-tumor 
(GVT) effect, coupled with the benefit derived from pre-transplant conditioning6,7. 
This GVT effect is primarily derived from donor T cells but can also be attributed 
to natural killer (NK) cells and B cells8. However, B cell responses against tumors 
are largely driven by T-B cell interactions, and B cell reconstitution is delayed after 
allo-HCT9. With regards to NK cells, generation occurs early after transplant, and 
have been demonstrated to possess GVT capability10,11. While this treatment holds 
much promise, poor functionality in haplo-identical recipients early after transplant 
as well as graft failure due to large number of stem cells that must be infused, 
especially in the case of T cell depleted (TCD) transplants, remain obstacles for 
clinical success12. 
The success of allo-HCT is compromised by the development of GVHD, a 
complication mediated by mature donor T cells present in the graft that respond 
against normal host tissue. GVHD can occur in 2 phases: acute GVHD (aGVHD) 
and chronic GVHD (cGVHD), both of which are significant causes of morbidity and 
mortality after allo-HCT. The incidence of acute GVHD (aGVHD) has been 
significantly reduced over the past decade. Transplant-related mortality has 
declined with the implementation of reduced intensity conditioning (RIC) regimens, 
new GVHD prophylaxis strategies, and the development of molecular methods 
aiding in early detection of viral and fungal infections in concert with modern anti-
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infectious agents13–15. However, aGVHD still affects 20% to 70% of allo-HCT 
patients16. Current clinical regimens for GVHD patients are primarily based on 
nonspecific immunosuppressants for prophylaxis and treatment, such as 
calcineurin inhibitors or glucocorticosteroids, respectively17. These broadly-acting 
agents fail to induce immune tolerance, increase susceptibility to opportunistic 
infections, and compromise GVT activity18. Research in the field is focused on 
reducing GVHD without compromising the GVT effect. The current consensus on 
the initiation of GVHD pathophysiology can be divided into three primary phases: 
 
1) Host tissue injury caused by conditioning regimens leads to the release of 
proinflammatory cytokines. Tissue damage from pre- transplant conditioning 
regimens results in a prolonged (up to 12 weeks post allo-HCT) increase of 
various cytokines; these include interleukin 1β (IL-1β), interleukin 6 (IL-6), 
interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12 (IL-12), interleukin 21 
(IL-21), interleukin 23 (IL-23), transforming growth factor β (TGFβ) and tumor 
necrosis factor α (TNFα)19–21.  These cytokines are primarily produced by 
activated dendritic cells (DCs) in response to tissue damage and microbe 
exposure, in concert with release of damage associated molecular patterns 
(DAMPs), including high mobility group protein B1 (HMGB-1) and adenosine 
triphosphate (ATP), as well as pathogen associated molecular patterns 
(PAMPs), which include lipopolysaccharide (LPS) and peptidoglycan. Both 
DAMPs and PAMPs can activate APCs, such as DCs and macrophages.  
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2) Donor T cell activation by activated APCs leads to differentiation into 
effector T cells, such as T helper type 1 (Th1) and T helper type 17 (Th17), 
both of which are pathogenic and associated with GVHD severity and 
mortality22.  
3) Effector T cell migration and target tissue destruction by activated donor T 
cells results in the initiation of GVHD22,23.  
 
A myriad of cytokines, chemokines, receptors, and transcription factors are 
associated with T cell activation and associated inflammation, hence playing a 
central role in the development of GVHD. Classically, Th1 cells are believed to play 
a critical role in the induction of GVHD; although our group and others have 
demonstrated that Th17 cells also contribute15. By targeting Th1 and Th17 specific 
transcription factors, T-box transcription factor TBX21 (T-bet) and Retinoic acid- 
related orphan receptor gamma (RORγt), respectively, it was observed that both 
Th1 and Th17 subsets contribute to GVHD development; yet either lineage alone 
is sufficient to induce GVHD25,26. Thus, both lineages must to be blocked in order 
to control GVHD. Efficacy of targeting these T cell differentiation pathways at the 
cytokine level are under investigation in clinical trials. Strategies for 
protecting/promoting prompt repair of target tissues may also reduce GVHD 
severity. 
 
I.2. Acute GVHD (aGVHD)  
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Acute GVHD is manifested by a strong inflammatory component resulting from 
robust donor T cell activation and expansion. Prior to transplant, conditioning 
regimens involving chemotherapy and/or irradiation cause damage to host 
epithelial tissues and subsequent release of danger signals such as chemokines 
and cytokines. The inflammatory milieu is then amplified by an activated innate 
immune response, consisting of APCs, natural killer cells (NK cells), neutrophils, 
and macrophages23. Donor CD4 and CD8 T cell recognition of major or minor 
histocompatibility antigens, directly or indirectly, by host and donor APCs in 
conjunction with activation of the innate immune response creates a “cytokine 
storm” consisting of such components as interferon gamma (IFN), TNFα, IL-6, IL-
12 and IL-23, among others18,27. The aforementioned combination of inflammatory 
factors culminates in T cell infiltration and subsequent destruction of host tissues, 
namely the skin, lung, liver and gastrointestinal tract (GI tract)27–30. 
 
I.3. Chronic GVHD (cGVHD)  
Chronic GVHD is widely systemic and can affect essentially any of the major organ 
systems18,31. While largely undefined, the origin of cGVHD pathogenesis has been 
linked to thymic damage caused by conditioning, resulting in aberrant selection 
and subsequent release of allo/autoreactive T cells32. Older patients receiving RIC 
have also been observed with cGVHD, which is potentially due to reduced thymic 
reserve/ function33,34. The activation of these T cells results in cytokine production 
and consequential activation of macrophages and fibroblasts. Chronically 
stimulated donor T cells interact with bone marrow-derived B cells and produce 
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additional factors contributing to fibroblast proliferation and activation32,35. In 
particular, T follicular helper (Tfh) cells interact with B cells via CD40L-CD40 to 
promote B cell proliferation, differentiation, and antibody isotype switching36. 
These Tfh-B cell interactions subsequently lead to germinal center formation in 
which antibody diversification and affinity maturation occur, ultimately leading to 
an adaptive immune response32,35,36. The resultant autoantibody production and 
tissue fibrosis lead to end organ damage37.  
 
I.4. The IL-12 Family of Cytokines and Receptors  
The IL-12 family of cytokines can direct the donor immune response to execute a 
range of proinflammatory and immunosuppressive functions that are relevant in 
GVHD (Fig. 1). They are primarily secreted by cells of myeloid origin in response 
to inflammatory stimuli, such as microbial products or fungal infections38. While 
part of the type 1 hematopoietin family of cytokines, IL-12 family members are 
unique in that each member is comprised of two different subunits, or 
heterodimers,  in which either the  or   subunit is shared among the others39. 
The -subunits include p19 (IL-23/IL-39), IL-27p28 (IL-27), and p35 (IL12/IL-35). 
The - subunits include p40 (IL-12/IL-23) and Epstein-Barr virus-induced gene 3 
(EBI3) (IL-27/IL-35/IL-39)40. Further, each cytokine signals through a distinct 
heterodimeric receptor that is associated with its cognate subunits: IL-12R (IL-
12Rβ2/IL-12Rβ1), IL-23R (IL-23R/IL-12Rβ1), IL-27R (IL-27R/gp130), IL-39R 
(IL-23R/gp130), and IL-35R (IL-12Rβ2/gp130)39,40. The functionality of each 
respective cytokine and receptor combination ranges from proinflammatory to 
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immune suppressive in a host of pathological and physiological conditions. Yet, 
similar subunits and receptors involved in proinflammatory functions can also form 
suppressive complexes, as in the case of IL-12Rβ2, involved in IL-12 and IL-35 
signaling. Therefore, deciphering the contributions of each cytokine/ receptor 
subunit combination is critical to understanding the immune response as a whole; 
the context of allo-HCT is no exception.  
 
 
Figure 1. The IL-12 family: cytokines, receptors, JAK-STAT signaling, influence on CD4+ T 
cell differentiation and subsequent effect on GVHD severity after allo-HCT (‘+’ and ‘–’ 
denote increase or decrease in GVHD severity, respectively. Listed from top to bottom) IL-12 is a 
heterodimer composed of p35 and p4041. Upon ligation, IL-12 signals through IL-12R𝛃1 and IL-
12R𝛃2, which form the receptor complex for IL-12 (IL-12R), subsequently leading to JAK2-STAT4 
signal transduction and a positive feedback loop for Th1 differentiation42–45. While its role in Th1 
differentiation and IFN𝛄 production has been shown to drive GVHD, there are conflicting reports 
 8 
concerning the specific requirement of IL-1246,47; p35 can also associate with EBI3 to form IL-35, 
and p40 is the shared subunit with IL-23 (+). IL-23 is a heterodimer composed of p19 and p4048. 
IL-23R associates with JAK2 to induce primarily STAT3 phosphorylation but also STAT4 to a 
lesser degree26,49–51. IL-23 signaling results in stabilization cues for Th17 cells and has also been 
implicated exacerbation of intestinal GVHD (++)52–56. IL-27, composed of p28 and EBI3, ligation 
to IL-27R/ gp130 promotes IL-10 production by Tr1 cells via STAT1 at early time points post- 
BMT and plays a role in hindering GVHD- induced inflammation57. However, IL-27 also inhibits 
Treg generation and may promote Th1 differentiation and function (+/-)58,59. IL-35 is composed of 
p35 and EBI3. IL-35 can signal through any combination of IL-12R𝛃2 and gp130 was recently 
described as a potent immunoregulatory cytokine secreted by both T and B regulatory cells39,60,61. 
IL-35 has been reported to suppress GVHD development. IL-39 is the most recent addition to the 
family and is composed of p19 and EBI3, which signal through STAT3 and STAT1. There are no 
reports of its function in the context of allo-HCT. 
*reported to promote GVHD through increased Th1 and decreased Treg differentiation; yet also 
dampen GVHD severity via Tr1 during induction phase  
 
I.4.a. IL-12/IL-12R  
IL-12 consists of p35 and p40, and acts primarily on NK cells and T cells33,41. IL-
12Rβ1 binds to IL-12Rβ2 to form the receptor for IL-12 (IL-12R)41,62. Upon 
ligation, IL-12Rβ1 binds to Tyrosine kinase 2 (Tyk2) while IL-12Rβ2 binds to 
Janus Kinase 2 (JAK2). Tyk2 and JAK2 then phosphorylate tyrosine residues 
primarily on signal transducer and activator of transcription 4 (STAT4). 
Ultimately, the STAT4 complex trans locates to the nucleus and binds to the IFNγ 
promoter; Jun oncogene (c-Jun) is also recruited to the IFNγ promoter via 
STAT442,43,63, potentiating IFNγ transcription and Th1 differentiation. In a STAT4 -
dependent manner, IL-12 also promotes expression of Interferon regulatory 
factor 1 (IRF1) and 4 (IRF4), transcription factors required for Th1 differentiation 
64,65. Notwithstanding the contribution of IL-12 to Th1 differentiation, IL-12/IL-12R 
also promotes T-cell proliferation and adhesion during activation. It has been 
reported that  IL-12 contributes to expression of Interleukin 2 receptor α (IL-2Rα) 
by recruiting STAT4 and c-Jun to the promoter of IL-2R, thereby enhancing T cell 
proliferation66,67. IL-12 -induced STAT4 activation also culminates in P-selectin 
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ligand formation, which augments T cell adhesion during differentiation68–71. 
Furthermore, activation of IL-12/IL-12R signaling induces both positive and 
negative feedback queues which can either strengthen or reduce IL-12 signaling, 
respectively. For instance, STAT4 activation fosters transcription of IL-12Rβ2 and 
Interleukin 18 receptor 1 (IL-18R1), which cooperate to amplify IL-12 signaling 
and Th1 cell differentiation. While IL-12R signaling can promote proliferation via 
STAT5-JAK2 interactions, evidence exists that STAT5A can suppress IL-12 -
induced Th1 cell differentiation through the induction of Suppressor of cytokine 
signaling 3 (SOCS3)50. However, this report demonstrated that SOCS3 activity 
inhibits IL-12 signaling by binding to the STAT4 docking site of the IL-12Rβ2 
subunit72,73. Hence, IL-12 is predominately associated with Th1 differentiation, 
yet may simultaneously hinder this effect through mobilization of STAT5A 
depending on the context of disease or environment. IL-12 promotes the 
differentiation of primed CD4+ T cells into Th1 cells, which express Tbet, produce 
IFNγ, and play a critical role in driving GVHD25,62. On the other hand, IL-12 
negatively regulates T helper type 2 (Th2) transcription factors and associated 
cytokine production74. As such, IL-12R2 expression is absent on Th2 cells but 
upregulated in Th1; an increase in Th2 differentiation is associated with reduced 
acute GVHD yet can exacerbate chronic GVHD75,76. In addition, CD40-CD40L 
interactions between T cells and APCs can fuel IL-12 production by APCs, which 
amplify innate immune cell responses through IFN production77. With regards to 
the IL-12 cytokine itself, the pool of available data is somewhat contradictory in 
the context of aGVHD. IL-12 has been reported to drive GVHD due to its 
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stimulatory effect on Th1 cells78,79. IL-12 serum levels in aGVHD patients are 
increased compared to healthy controls, yet no correlation between higher grade 
GVHD (II-IV) and IL-12 has been observed80 (Table 1). Conversely, exogenous 
IL-12 administration was suggested to be protective in GVHD via an IFNγ-
dependent mechanism81. Previous studies observed that a single injection of IL-
12 at the time of allo-HCT stifles GVHD in myeloablative-conditioned 
recipients46,47,81. The protective or pathogenic role of IL-12 seemingly relies on 
the dose and timing IL-12 injection, and irradiation type for the recipient 
conditioning regimen in murine BMT models82. In NK cells, IL-12 induces 
cytotoxic events through STAT4 and subsequent activation of the Perforin 1 
(perforin) gene promoter83. A recent report a describes IL-12/IL-18 activated 
donor NK cells mitigate GVHD but enhance GVT activity84. Apart from advocating 
Th1 responses, IL-12 plays a critical role in T follicular helper cell (Tfh) 
differentiation and function through STAT4 and Tbet85,86. Consistent with the 
crucial role of Tfh cells in cGVHD pathogenesis, administration of anti-p40 mAb 
in recipient mice significantly reduced Tfh generation and scleroderma 
manifestations of cGVHD after allo-HCT57. Thus, targeting one or more of the IL-
12 cytokine/receptor subunits represents a promising therapeutic strategy to 
reduce cGVHD. 
 
I.4.b. IL-23/IL-23R   
IL-23 consists of p19 and p40. The IL-23R is a heterodimer comprised of IL-12Rβ1 
and IL-23R. IL-23R associates with JAK2 and, in a ligand-dependent manner, 
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with STAT3. IL-23- induced activation of STAT3 leads to direct binding of 
phosphorylated STAT3 to IL-17A and IL-17F promoters. STAT3 up-regulates the 
expression of RORγt, the master transcription factor of Th17, which is critical for 
the expression of two members of the Interleukin-17 family, IL-17A and IL-17F87–
89. SOCS3 inhibits JAK2 activity, hence decreasing IL-17A and IL-17F 
expression87. Hence, IL-23 signaling regulates Th17 cells.  IL-23 plays an 
important role in expanding and maintaining the Th17 cell population, a T cell 
subset involved in homeostatic antimicrobial immune responses as well as in the 
propagation of many autoimmune diseases90. IL-23 is an indispensable factor for 
promoting pathogenicity of Th17 cells, yet is not required for initial differentiation91–
94. IL-23 has been shown to control Th17 responses through regulating T cell 
metabolism. TCR stimulation induces GLUT-1 surface expression and subsequent 
lactate production, promoting glucose uptake95,96. T cells under Th17 polarizing 
conditions undergo a HIF1-α- dependent metabolic switch to glycolysis, and data 
indicates that IL-23 might contribute to this effect via PKM2 and HIF1-α97. Notably, 
allogeneic T cells were shown to depend on glycolysis for effector function during 
GVHD development, yet a connection to IL-23 and glycolysis has not been 
demonstrated. HIF1-α induction has also been associated with IL-23 production in 
dendritic cells; this link between HIF1-α and PKM2 has been previously 
established in cancer cells98–100. Therefore, PKM2 may possess more than one 
function in addition to its role in glycolysis manifested by transcriptional activation 
as a protein kinase101. Taken together, IL-23 signaling through PKM2/STAT3 may 
directly contribute to the metabolism of Th17 cells and, in concert with IL-6, could 
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represent an essential factor for lineage commitment102. Glucocorticoid-induced 
protein kinase 1 (SGK1) is critical for IL-23R expression through deactivating 
murine Foxo1, which directly represses IL-23R expression103. SGK1 is essential 
for the induction of pathogenic Th17 cells and implicates environmental factors, 
such as a high-salt diet, as triggers to Th17 development and subsequent tissue 
inflammation104. Lastly, while Blimp-1 IL-23-dependent Blimp-1 enhances Th17 
pathogenic factors such as GM-CSF and IFNγ, and co-localizes with RORγt and 
STAT-3 at Il23r, Il17a, and Csf2 enhancer sites105. Studies show IL-23 signaling 
contributes to the pathogenesis of various autoimmune diseases. In mice, it was 
demonstrated that bacteria-driven innate colitis is associated with an increased 
production of IL-17A and IFNγ in the colon. Stimulation of intestinal leukocytes with 
IL-23 induced the production of IL-17 and IFNγ exclusively by innate lymphoid cells 
expressing IL-23R, which were demonstrated to accumulate in the inflamed colon. 
These results identified a previously unrecognized IL-23-responsive innate 
lymphoid population that mediates intestinal immune pathology and may therefore 
represent a target in inflammatory bowel disease106–108. Intestinal IL-23-responsive 
innate cells are also a feature of T cell-dependent models of colitis, which 
resembles many of the features seen in intestinal GVHD with respect to T cell 
infiltration resulting in inflammation and gut injury. The transcription factor RORγt 
controls IL-23R expression, as it was shown that Rag/Rorc-null mice failed to 
develop innate colitis which is dependent on IL-23106. In addition, expression of IL-
23 and IL-23R was increased in the tissues of patients with psoriasis109. Injection 
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of a neutralizing monoclonal antibody to IL-23p19 in a xenotransplant mouse 
model showed IL-23-dependent inhibition of psoriasis109. 
 
I.4.c. IL-39/IL-39R 
IL-39 has been proposed to consist of p19 and EBI3, and is the most recent 
addition to the family110. Wang et al. published the first report describing the 
function of an additional heterodimer that involves p19 complexed with a subunit 
other than p40. IL-39 is secreted by activated B cells and was demonstrated to be 
significantly elevated in lupus models compared to other IL-12 members using 
MRL/lpr mice110. The receptor for IL-39 was determined to be formed by 
dimerization of IL-23R and gp130 and signal through STAT1 and 3. While 
associated with neutrophil differentiation and expansion, the proinflammatory 
effects of IL-39 have yet to be fully defined. In a different report by Ramnath et al, 
IL-39 was shown to be secreted by keratinocytes and contribute to wound 
healing111. While the function of IL-39 may be context dependent, these disparate 
reports indicate that IL-39 may also act on a broad range of cell types. Hence, 
further clarification regarding the general role of IL-39 in immunity is required in 




Table 1: Expression levels of IL-12 family cytokines in aGVHD patients. Representative table 
of IL-12, IL-23, IL-27 and IL-35 levels detected in the serum of patients with aGVHD. Upward 



















II. Targeting p40 to reduce acute and chronic GVHD 
II.1. Abstract  
Graft-versus-host disease (GVHD), in both its acute (aGVHD) and chronic 
(cGVHD) forms, remains a major obstacle impeding successful allogeneic 
hematopoietic stem cell transplantation (allo-HSCT). T cells, in particular 
pathogenic Th1 and Th17 subsets, are a driving force for the induction of GVHD. 
IL-12 and IL-23 cytokines share a common p40 subunit and play a critical role in 
driving Th1 differentiation and in stabilizing the Th17 phenotype, respectively. In 
our current study, we hypothesized that p40 is an essential cytokine in the 
development of GVHD. By using p40-deficient mice, we found that both donor- 
and host-derived p40 contribute to the development of aGVHD. Neutralization of 
p40 with an anti-p40 mAb inhibited Th1- and Th17- polarization in vitro. 
Furthermore, anti-p40 treatment reduced aGVHD severity while preserving the 
graft-versus-leukemia (GVL) activity. Alleviation of aGVHD was associated with an 
increase of Th2-differentiation and a decrease of Th1 and Th17 effector T cells in 
the GVHD target organs. In addition, anti-p40 treatment attenuated the severity of 
sclerodermatous cGVHD. These results provide a strong rationale that blockade 
of p40 may represent a promising therapeutic strategy in the prevention and 






Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative 
option for many hematopoietic neoplastic diseases. However, its efficacy is limited 
by the occurrence of graft-versus-host disease (GVHD), which remains the major 
cause of morbidity and mortality in the recipients of allo-HSCT112,113. Generally, 
GVHD attributes its detrimental effects to an immunological attack on recipient 
parenchymal organs by donor pathogenic cells transplanted in the graft114. 
According to distinct pathophysiology and clinical manifestations, GVHD can be 
divided into two forms: acute GVHD (aGVHD) and chronic GVHD (cGVHD)112. 
Donor T cell-mediated injuries in the liver, skin and gut are the main characteristics 
of aGVHD113,114. cGVHD manifests itself with more extensive organ involvement 
and many autoimmune and fibrotic features caused by alloreactive T and B 
cells115. In the clinic, many patients have an overlap syndrome in which features 
of aGVHD and cGVHD appear together115,116. Thus, finding shared therapeutic 
targets of aGVHD and cGVHD could be a highly efficient method to control GVHD 
and increase the overall success of allo-HSCT. 
T-helper (Th), CD4 cells can differentiate into several distinct subsets, such as: 
Th1, Th2, Th17, and T regulatory cells (Tregs), depending on the signals 
encountered. Among these, Th1 and Th17 are the major pathogenic subsets that 
induce aGVHD and cGVHD74,117–119. Paradoxically, exacerbated aGVHD was 
observed in mice receiving IFNγ−/− or IL-17A−/− T cells120,121. This phenomenon 
occurs because IFNγ−/− T cells produce more IL-17A, whereas IL-17A−/− T cells 
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produce more IFNγ. These results indicate that Th1 and Th17 lineages are 
mutually inhibitory, and that each alone is sufficient to induce GVHD. Furthermore, 
our recent work clearly demonstrates that it is necessary to block both Th1 and 
Th17 lineages in order to control the development of aGVHD25. 
Cytokines produced by antigen presenting cells (APCs) are critical factors in T-cell 
activation and differentiation, among which IL-12 and IL-23 play important roles in 
driving Th1 development and stabilizing the Th17 phenotype, respectively39. IL-12 
and IL-23 belong to the IL-12 family of cytokines and function as master regulators 
for innate and adaptive immunity122. Both IL-12 and IL-23 are heterodimeric 
cytokines, which have a shared p40 subunit, paired with either an α chain p35 or 
p19, respectively39. Ustekinumab is an anti-p40 mAb specific for amino acids 1–
88 that specifically blocks the interaction of p40 with the IL-12Rβ1 chain in the IL-
12 and IL-23 receptors in human123. This mAb is approved by the U.S. Food and 
Drug Administration (FDA) for the treatment of moderate-to-severe psoriasis and 
shows impressive efficacy in the clinic123,124. 
Increased p40 mRNA has been found in GVHD target organs, which is relevant to 
the localized production of IFNγ after allogeneic bone marrow transplantation (allo-
BMT)125. In the current study, we hypothesized that the blockade of p40 could 
alleviate GVHD by regulating the differentiation and function of Th1 and Th17 cells 
after (allo-BMT). Here, we provide evidence that both donor- and host-derived p40 
contribute to the development of aGVHD. Overall, neutralizing p40 efficaciously 
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reduces Th1 and Th17 polarization and alleviates the severity of aGVHD and 
cGVHD while preserving the graft-versus-leukemia (GVL) activity. 
II.3. Materials and methods  
II.3.a. Mice 
C57BL/6 (B6; H-2b), B6.Ly5.1 (H-2b), BALB/c (H-2d), FVB (H-2q) mice were 
purchased from the National Cancer Institute/National Institute of Health. C3.SW-
H2b/SnJ (H-2b), B10.D2 (H-2d), and p40−/− mice on B6 background mice were 
purchased from the Jackson Laboratory. All animals were housed in the American 
Association for Laboratory Animal Care–accredited Animal Resource Center at 
Medical University of South Carolina (MUSC, Charleston, SC). Experiments were 
carried out under protocols approved by the Institutional Animal Care and Use 
Committee (IACUC) at MUSC. 
II.3.b. Cell staining and flow cytometric analysis 
Mononuclear cell isolation from recipient spleen and liver was carried out as 
previously described25. Standard flow cytometric surface staining was used. For 
intracellular cytokine staining, cells were stimulated with 50ng/ml PMA (Sigma-
Aldrich), 500ng/ml ionomycin (Sigma-Aldrich) and 0.7 μl/ml Golgi Plug (BD 
Biosciences) incubated at 37 °C for 4 hours before staining as recommended by 
the manufacturer. The flow antibodies used were as follows: CD4-V450 (clone 
RM4-5, BD), CD8-APC-Cy7 (clone 53-6.7, BD), B220-PE (clone RA3-6B2, 
eBioscience), H2Kb-APC (clone AF6-88.5.5.3, eBioscience), H2Kq-Alexa Fluor 
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647 (clone KH114, Biolegend), CD45.1-FITC (clone A20, BD), IFNγ- Percp-Cy5.5 
(clone XMG1.2, eBioscience), IL-4-PE (clone 11B11, BD), IL-5-PE (clone TRFK5, 
eBioscience), IL-17-PE-Cy7 (clone TC11-18H10.1, Biolegend), CXCR3-Biotin 
(clone CXCR3-173, eBioscience), PD-1-PE (clone J43, eBioscience), CXCR5-PE-
Cy7 (clone SPRCL5, eBioscience), Ly9.1-Biotin (clone 30C7, BD), Streptavidin-
PE-Cy7 (BD), and Streptavidin-APC-Cy7 (BD). Stained cells were analyzed using 
Diva software, LSR II (BD Biosciences, San Jose, CA) and FlowJo (TreeStar, 
Ashland, OR). 
II.3.c. In vitro generation of Th1 and Th17 cells 
Splenocytes were isolated from normal B6 mice and were CD8/CD25-depleted 
using negative selection. CD8/CD25-depleted splenocytes were cultured with IL-2 
(2ng/ml) or anti-CD3 (1μg/ml) plus IL-12 (10ng/ml), IFNγ (1000U/ml) and anti-IL-4 
(10μg/ml) for Th1 generation. For Th17-generation, cells were stimulated with anti-
CD3 (1μg/ml) in the presence of IL-6 (10ng/ml), TGF-β (5ng/ml), anti-IFNγ 
(10μg/ml) and anti-IL-4 (10μg/ ml). Cells were cultured in a 24-well plate in the 
presence of isotype or anti-p40 mAb at the concentrations indicated for 3 days, 
and then tested for the expression of intracellular IFNγ and IL-17. Supernatant from 
the cell culture was harvested, diluted 2 times, and measured IFNγ production 
using ELISA. 
II.3.d. GVHD models 
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T cells were purified from spleen and lymph node cells by negative selection using 
magnetic beads as previously described25. T-cell purity was typically more than 
95%. T-cell- depleted bone marrow (TCD-BM) was prepared by complement lysis 
as previously described and transferred at 5 × 106/mouse25. B6→BALB/c (1 × 106 
T cells) and FVB→B6 (2 × 106 T cells) MHC-mismatched BMT models were used 
for aGVHD experiments. B10.D2 →BALB/c (5 × 106 splenocytes) MHC-matched, 
minor histocompatibility antigen (MiHA)-mismatched BMT model was used for 
cGVHD experiments. Recipient mice (8–10 weeks of age) were conditioned with 
total body irradiation (TBI) administered at 700cGy for BALB/c < 23g or 750cGy 
for those ≥ 23g of initial body weight and 950cGy for B6 mice < 23g or 1000cGy 
for those ≥ 23g using an X- RAD 320 X-ray Irradiator (Precision X-ray Inc., North 
Branford, CT). Within 24 hours after TBI, recipient mice were transplanted with 
TCD-BM alone or together with purified T cells or splenocytes. The recipient mice 
in aGVHD experiments were monitored for body weight and survival twice weekly. 
The recipient mice in cGVHD experiments were monitored for survival and clinical 
signs such as weight loss, posture, activity, fur texture, and skin integrity weekly126. 
II.3.e. Leukemia/lymphoma models and Bioluminescent imaging (BLI) 
B6→BALB/c MHC-mismatched and C3.SW-H2b/SnJ→B6 MHC-matched, MiHA- 
mismatched BMT models were used to examine the GVL effects of donor T cells. 
B6→BALB/c (1 × 106 T cells) recipients were injected with 2×103 luciferase-
transduced A20 B cell lymphoma cells, whereas C3.SW-H2b/SnJ→B6 (3 × 106 
CD44− T cells) recipients with 1×105 C1498 luciferase-transduced acute myeloid 
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leukemia cells at the time of BMT. The recipient mice were monitored for body 
weight and survival twice weekly, and clinical score and tumor growth weekly. Mice 
were injected i.p. with luciferin (150mg/kg) and then anesthetized with isoflurane 
gas using Xenogen XGI Gas Anesthesia System. The BLI was performed by using 
the IVIS system (Xenogen). The imaging data were analyzed using Living Image 
Software (Xenogen). The mortality caused by tumor relapse or GVHD was 
distinguished by BLI signal indicative of tumor relapse and weight loss indicative 
of GVHD. 
II.3.f. Antibody treatment in vivo 
Anti-p40 mAb (CNTO3913) and its isotype control (CNTO6601) were kindly 
provided by Janssen Research & Development, LLC, Spring House, PA, USA. 
These mAbs were injected i.p. at 25mg/kg body weight on day 0 and then 12.5 
mg/kg twice weekly for 4 weeks after BMT. 
II.3.g. Statistics 
The percentages of body weight change, percentages of cell types, absolute 
numbers of cells, and clinical scores in WT vs. KO, or isotype vs. anti-p40 
treatment were compared using 2-tailed student t test. The Log-rank test was used 




II.4.a. Donor- and host-derived p40 contribute to aGVHD severity. To 
examine the role of p40 produced by donor cells in mediating aGVHD, we 
performed an allo-BMT using p40-deficient (p40−/−) mice on B6 background as 
donors and tested the effects of p40 deficiency on donor BM and T cells in the 
development of aGVHD. The BALB/c recipients of p40−/− BM and T cells had 
significantly improved survival compared to those that received WT cells (p = 
0.046) (Figure 1A), yet weight loss was similar (p = 0.184) (Figure 1B) between 
the two groups. Consistent with alleviation of aGVHD, the recipients of the 
p40−/− graft had improved donor CD4 T- and B-cell reconstitution compared to 
those recipients of WT graft (p = 0.04 and 0.04, respectively) (Figure 1C). 
Furthermore, the function of T and B cells in the recipients of p40−/− graft was 
significantly improved compared to those in the recipients of WT graft (p = 0.03 
and 0.001, respectively) (Figure 1D). These results indicate that donor-derived 
p40 contributes to the development of aGVHD after allogeneic BMT. Because 
p40 can be produced by either donor or host APCs and host APCs are critical to 
inducing aGVHD127,128, we assessed the role of host-derived p40 on the 
development of aGVHD. Host-derived p40 had little or no effect on donor BM 
engraftment, because WT and p40−/− recipients infused with BM alone had 
comparable outcomes (Figures 2A and 2B) and similar CD4, CD8 T- and B-cell 
reconstitution 80 days post BMT (p =0.33, 0.78, and 0.32, respectively) (Figures 
2C and 2D). However, p40−/− recipients transferred with donor allogeneic T cells 
had significantly improved survival (p = 0.015) (Figure 2A) and increased donor 
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B-cell reconstitution (p = 0.02) (Figures 2E and 2F). These data suggest that 
host- derived p40 also significantly contributes to the development of aGVHD.  
 
  
Figure 1. Role of donor-derived p40 in aGVHD  
BALB/c mice were lethally irradiated at 700–750 cGy and transplanted with WT graft (5 × 106 BM 
and 5 × 106 T cells) or p40−/− graft from mice on B6 background. Recipient mice were monitored 
for survival (A) and body weight changes (B) over time. Data were pooled from 2 replicate 
experiments with total 10–12 mice per group. (C) Spleens were collected from each survived 
recipient 80 days after BMT, and stained for expression of CD4, CD8, B220 and H2Kb (donor 
marker). Absolute numbers of CD4+, CD8+ or B220+ donor cells were calculated and presented 
in a per spleen basis. (D) T- and B-cell function was measured by stimulating spleen cells with 
anti-CD3 or LPS for 3 days. Proliferation was assessed using [3H]-TdR incorporation assay. Data 






Figure 2. Role of host-derived p40 in aGVHD  
WT or p40−/− B6 mice were lethally irradiated at 950–1000 cGy. These recipients were then 
transplanted with 5 × 106/mouse TCD-BM alone or with 2 × 106/mouse of total T cells isolated 
from FVB donor mice. Recipient mice were monitored for survival (A) and body weight changes 
(B) over time. Data were pooled from 3 replicate experiments with total 16 mice per group. Upon 
completion of the experiment on day 80, spleens were collected from surviving recipients for cell 
counting and FACS analysis. Percentages or absolute numbers of donor-derived (H2Kq+) CD4, 
CD8 T cells and B cells were shown in BM alone recipients (C–D) and BM plus T cell groups (E–





 II.4.b. Anti-p40 mAb inhibits the activity of IL-12 and IL-23 in T-cell 
polarization in vitro. Using gene deletion (p40−/− mice), the data presented 
above indicate that IL-12/23p40 may be a valid therapeutic target for the control 
of aGVHD. To translate these findings to a more practical, therapeutic approach, 
we then focused our attention on systemically neutralizing IL-12 and/or IL-23 p40 
using an anti-p40 mAb. We first tested whether anti-p40 mAb could block Th1 
and Th17 polarization in vitro by antagonizing the activity of IL-12 and IL-23. 
Indeed, anti-p40 mAb inhibited IFNγ production by T cells that were stimulated 
with IL-12 plus IL-2 or anti-CD3 under Th1 polarizing conditions in a dose-
dependent manner (p = 0.007 and 0.02, respectively) (Figure 3A). Anti-p40 
treatment also inhibited intracellular expression of IFNγ and IL-17 in T cells 
stimulated by IL-12 (Th1 condition) and IL-23 (Th17 condition), respectively 
(Figure 3B and 3C). These data indicate that anti-p40 mAb is efficacious in 
suppressing Th1 and Th17 polarization in vitro.  
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Figure 3. Effect of anti-p40 mAb on T-cell polarization in vitro 
(A) CD8/CD25- depleted splenocytes were cultured with IL-2 or anti-CD3 plus IL-12 in the  
presence of isotype or anti-p40 mAb at the concentrations indicated for 3 days (details were 
described in the Material and Methods). Culture supernatants were harvested and IFNγ was 
measured by ELISA. The levels of IFNγ were reflected by average OD415 in duplicate wells from 
one of two replicate experiments. (B) CD8/CD25-depleted splenocytes were cultured in Th1 
conditions or Th17 conditions for 3 days. Cultured cells were harvested and stained for the 
expression of surface CD4 and intracellular IFNγ and IL-17 on gated CD4+ cells (C–D). The data 
present 5 replicate wells in each group from one of two replicate experiments. *p < 0.05, **p < 




II.4.c. Neutralizing p40 alleviates aGVHD. Since anti-p40 mAb significantly 
reduced Th1 and Th17 polarization in vitro, we further hypothesized that 
neutralizing p40 would attenuate aGVHD after allo-BMT. By using the B6 → 
BALB/c BMT model, we found that systemically giving anti-p40 mAb significantly 
improved recipient outcomes as reflected by significantly better survival and less 
body weight loss compared to WT controls (p = 0.004 and 0.001, respectively) 
(Figures 4A and 4B). These data demonstrate that systemic administration of 




Figure 4. Effect of neutralizing p40 on aGVHD development  
BALB/c mice were lethally irradiated at 700cGy and transplanted with 5 × 106/mouse TCD- BM 
alone or together with total T cells at 1 × 106/mouse from WT B6 mice. Recipient mice were 
injected i.p. with isotype or anti-p40 mAb at 25 mg/kg body weight on day 0 and then 12.5 mg/kg 
twice weekly for 4 weeks. Recipient survival (A) and body weight changes (B) were monitored 
over time. Data were pooled from 2 repeated experiments with 10 mice in each group. **p < 0.01.  
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To further understand the mechanism by which neutralizing p40 reduces aGVHD 
severity in vivo, we investigated how anti-p40 treatment affects donor T-cell 
activation, differentiation and migration after allo-BMT. Treatment with anti-p40 
mAb had no impact on IFNγ- or IL-17-producing T cells, but significantly 
increased IL-4/5-producing CD4 T cells in recipient spleens at 14 days post-BMT 
(p = 0.028) (Figures 5A and 5C). However, anti-p40 treatment significantly 
reduced IFNγ-producing CD4 and CD8 T cells in the recipient liver, a major 
target organ of aGVHD (p = 0.012 and 0.043, respectively) (Figures 5B and 5D). 
In addition, neutralization of p40 also significantly reduced the number of IL-17-
producing CD8 T cells in the recipient livers (p = 0.047) (Figure 5D). Anti-p40 
treatment had no impact on Treg differentiation between the two groups (data not 
shown). Thus, in murine models, neutralizing p40 promoted Th2-differentiation 
while reducing IFNγ and IL-17 production in GVHD target organs after allo-BMT. 
Because donor T-cell migration to target organs is an essential step for the 
development of aGVHD129, we further tested the migratory ability of donor T cells 
during p40 neutralization. As shown in Figure 5E, there were significantly fewer 
CD4 and CD8 donor T cells in recipient liver 14 days after anti-p40 treatment (p = 
0.03 and 0.016, respectively). Given CXCR3 is a key chemokine receptor 
modulating T cell migration to the liver, we measured CXCR3 expression on 
donor T cells and found that anti-p40 treatment significantly decreased CXCR3 
expression on donor CD4, but not CD8, T cells (p = 0.004 and 0.933, 
respectively) (Figure 5F). These data suggest that anti-p40 treatment inhibits 
donor T-cell migration into the liver partially through down-regulation of CXCR3 
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expression. A trend of reduced pathology scores in the GVHD target organs, 
such as liver and gut, was observed in the recipients receiving anti-p40 mAb, 
although the difference did not reach statistical significance at 14 day post-BMT 
(data not shown). 
 
II.4.d. Neutralizing p40 maintained T-cell-mediated GVL activity after allo-
BMT. Preserving the GVL effect is of paramount importance when BMT is used 
as immunotherapy for hematologic malignances. Hence, we next asked whether 
neutralizing p40 would maintain GVL activity while alleviating aGVHD. Using B6 
→ BALB/c BMT model supplemented with A20 B-cell lymphoma cells, the 
recipients of BM alone plus A20 died within 2 weeks due to tumor relapse, and 
anti-p40 treatment without T cell infusion had no impact on tumor relapse 
(Figures 6A–C). The recipients transplanted with additional donor T cells 
survived significantly longer than those receiving BM alone, illustrated by little or 
no tumor signal. However, the majority of these recipients treated with the 
isotype control died from GVHD, as reflected by substantial weight loss and lack 
of BLI signal. We observed that anti-p40 treatment increased the rate and 
duration of recipient survival, although not significantly, and resulted in a 50% 




Figure 5. Effect of neutralizing p40 on donor T-cell differentiation and migration  
BALB/c mice were lethally irradiated at 700cGy and transplanted with 5 × 106/mouse TCD- BM 
alone from Ly5.1 B6 mice or together with total T cells at 1 × 106/mouse from Ly5.2 B6 mice. 
Recipient mice were treated with isotype or anti-p40 mAb as described in the Material and 
Methods. Fourteen days post-BMT, recipient spleens and livers were collected. Mononuclear 
cells were isolated for cell counting and FACS staining. (A–B) The expression of intracellular 
IFNγ, IL-4/5, and IL-17 is shown on gated donor H2kb+Ly5.1−CD4+ cells from the spleen and 
liver. Absolute numbers of IFNγ, IL-4/5, and IL-17 positive donor CD4 or CD8 T cells were shown 
in the spleen (C) or liver (D). (E) Absolute numbers of donor pathogenic H2kb+Ly5.1−CD4 or 
CD8 T cells in recipient livers were shown. (F) Percentage of CXCR3+ cells are shown on gated 
donor CD4 or CD8 T cells in recipient spleens. The data are pooled from 2 replicate experiments 
with 10 mice in each group. *p < 0.05 and **p < 0.01.  
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Figure 6. Role of neutralizing p40 on the GVL activity in MHC-mismatched BMT  
BALB/c mice were lethally irradiated and transplanted with 5 × 106/mouse TCD-BM alone or plus 
purified T cells from WT B6 mice at 1 × 106/mouse. Recipient mice were also infused with 2 × 
103 luciferase-transduced A20 cells at the day of BMT. Recipient mice were treated with isotype 
or anti-p40 mAb as described in the Material and Methods. Recipients were monitored for survival 
(A) and body weight change (B) for 60 days after transplant. Tumor growth was monitored using 
BLI on the dates indicated (C). The data are pooled from 2 replicate experiments with 10 mice in 
each group.  
 
Because MHC-matched, MiHA-mismatched BMT models provide additional 
clinical relevance, we next tested the effects of anti-p40 treatment on GVL 
activity by using a C3.SW-H2b/SnJ→B6 BMT model with C1498 murine acute 
myeloid leukemia cells. The recipients of BM alone had leukemic relapse and all 
mice were dead by day 40 after BMT (Figures 7A–C). The addition of donor T 
cells prevented leukemia relapse regardless of the treatment, and the mortality of 
recipients was essentially caused by GVHD. However, anti- p40 treatment 
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significantly prolonged recipient survival 50 days post-BMT (p = 0.026) (Figure 
7A). Taken together, these data indicate that anti-p40 treatment alleviated 
aGVHD and largely preserved GVL activity after allogeneic BMT. 
  
Figure 7. Role of neutralizing p40 on the GVL activity after MHC-matched and MiHA- 
mismatched BMT 
B6 mice were lethally irradiated and transplanted with 5 × 106/mouse TCD-BM alone or with 
purified CD44− T cells from C3.SW-H2b/SnJ mice at 3 × 106/mouse. Recipient mice were also 
infused with 1 × 105 luciferase-transduced C1498 cells at the day of BMT. Recipient mice were 
treated with isotype or anti-p40 mAb as described in the Material and Methods. Recipients were 
monitored for survival (A) and body weight change (B) for 50 days after transplant. Tumor growth 
was monitored using BLI on day 21 (C). The data are pooled from 2 replicate experiments with 12 




II.4.e. Neutralizing p40 alleviates cGVHD. We next wanted to determine 
whether neutralizing p40 could attenuate cGVHD. Using an MHC-matched but 
MiHA-mismatched B10.D2 → BALB/c model of sclerodermatous cGVHD, we 
found that anti-p40 treatment significantly alleviated the clinical manifestations of 
recipients at day 50 post-BMT (p = 0.036) (Figure 8A). In contrast to 30% 
mortality seen in the isotype group, all of the recipients survived with anti-p40 
treatment (p = 0.06) (Figure 8B). Consistent with the observed alleviation of 
cGVHD clinical manifestations, neutralizing p40 significantly increased donor 
derived CD4 and CD8 T-cell, but not B-cell, reconstitution in the recipient spleens 
60 days after BMT (p = 0.03, 0.036, and 0.143, respectively) (Figures 8C and 
8D). In addition, the generation of follicular T helper (Tfh) cells, which are critical 
for germinal center (GC) formation and cGVHD induction130, was inhibited by 
blocking p40 (p = 0.014) as measured by co-expression of CXCR5 and PD-1 
(Figures 8C and 8D). These data demonstrate that neutralizing p40 reduces the 
severity of cGVHD and improves immune reconstitution by constraining Tfh 
generation after allo- BMT. 
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Figure 8. Effect of neutralizing p40 on cGVHD  
BALB/c mice were lethally irradiated and reconstituted with 5 × 106/mouse TCD-BM alone or plus 
5 × 106/mouse splenocytes from B10.D2 donors. Recipient mice were treated with isotype or 
anti-p40 mAb as described in the Material and Methods. Recipients were monitored for clinical 
manifestations (A) and survival (B). Sixty days after transplant, recipient spleens were harvested 
and subjected to flow staining for the expression of Ly9.1 (recipient marker), CD4, CD8, B220, 
CXCR5 and PD-1. The representative flow figures (C) and statistic bar graph (D) are shown. The 









The current study provides data to demonstrate that both donor- and host-
derived p40 contributes to the development of aGVHD, and that neutralization of 
p40 reduces aGVHD severity while preserving GVL activity. Treatment with anti-
p40 mAb inhibits Th1 and Th17 polarization in vitro and promotes Th2 
differentiation in murine GVHD models. Anti- p40 treatment also inhibits donor T-
cell migration into GVHD target organs such as the liver. In addition, anti-p40 
treatment improves recipient clinical manifestations of cGVHD. 
Host APCs play a critical role in the initiation of aGVHD, while donor APCs also 
contribute to the activation and differentiation of donor allogeneic T cells131,132, 
and thus to the development of GVHD133. IL-12 and IL-23 are mainly produced 
by activated APCs, such as dendritic cells (DCs) and macrophages39. Along with 
modulating T-cell differentiation, IL-12 and IL-23 also act in an autocrine manner 
to enhance the ability of APCs to present antigen to T cells122. Our data 
illustrated that genetic deficiency of p40 in the donor or host significantly 
improved recipient survival after allo-BMT (Figures 1 and 2), indicating that both 
host APC- and donor APC-derived IL-12/23 promotes GVHD development. 
Consistent with this, we found that neutralization of p40 effectively inhibited Th1 
and Th17 polarization in vitro (Figure 3). In contrast, we were unable to 
demonstrate the effectiveness of p40 neutralization with mAb treatment in 
blocking Th1- or Th17- differentiation after allo-BMT (Figure 5). The potential 
explanation would be: 1) the dose of anti-p40 tested may not be sufficient to 
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block p40 in vivo; 2) other cytokines may compensate for the function of IL-12 
and IL-23 in the generation and maintenance of Th1 and Th17 subsets. 
However, anti-p40 treatment increased Th2-differention and decreased the 
numbers of Th1 and Th17 cells in recipient liver in the B6 → BALB/c model, 
which likely contributed to the alleviation of GVHD. Our observation is also 
consistent with a previous study that showed neutralizing IL-12 by anti-IL-12 Ab 
could attenuate aGVHD by driving Th2-differentiation in mouse models78. 
T-cell migration into peripheral organs is required for the induction of GVHD. We 
found that anti-p40 treatment significantly reduced donor T cells present in the 
liver, a key aGVHD target organ, which likely contributed to the alleviation of 
aGVHD (Figure 5). It is well accepted that the chemokine systems plays an 
important role in facilitating donor T cell migration to GVHD target organs. Among 
these, CXCR3 has been shown to play a pivotal role in Th1 migration134. In 
accordance with these observations, we found that the expression of CXCR3 on 
donor CD4 T cells was significantly reduced with anti-p40 mAb treatment, 
possibly due to the requirement of Th1-commitment to promote CXCR3 
expression134,135. Comparable CXCR3 expression in CD8 T cells was seen 
regardless of anti-p40 treatment, suggesting that CD8 T-cell trafficking is likely 
less dependent on CXCR3 expression, which is consistent with a published 
report that anti-CXCR3 treatment reduced CD4 but not CD8 T-cell infiltration in 
the central nervous system in response to virus infection135. However, there is 
another explanation that is relevant to the GVHD model used. In B6 to BALB/c 
model, GVHD is induced in a CD4-dependent manner, so we are more likely to 
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see differences in CD4 T cells. Whereas in MiHA-mismatched C3.SW- H2b/SnJ 
to B6 model used in Figure 5, GVHD is driven predominately by CD8 T cells. 
Thus, it is possible that CXCR3 may differentially be expressed on CD4 vs. CD8 
donor T cells in different models, which might be responsible for the distinct 
effects of anti-p40 on the migration of CD4 vs. CD8 T cells. 
Although significantly attenuated aGVHD was seen when blocking p40, the 
efficacy of preventing aGVHD was not as potent as was observed in our previous 
study with T-bet and RORγt blockade25. The moderate alleviatory effect of anti-
p40 treatment on aGVHD could be due to the insufficient treatment dose and 
compensatory cytokine mechanisms in vivo. In addition, p40 has also been 
shown to be a minor regulator of inflammatory responses, suggesting that 
blockade of p40 reduces IL-12 and IL-23 inflammatory cytokines but 
simultaneously decreases the small regulatory effect of p40. The p40 subunit is 
promiscuously expressed, while p35 and p19 are only secreted as part of the 
heterodimer when p40 is also produced by the same cells. As a result, p40 is 
often secreted in larger quantities than p35 and p1939,122,136. In mice, free p40 
can form homodimers or present as free monomers, both of which have been 
shown to be natural inhibitors of IL-12122,136–138. This could explain the potent 
effect of anti-p40 in polarizing conditions in vitro yet only moderate effects in vivo 
in regard to blockade of Th1/Th17 differentiation. The potentially inhibitory roles 
of p40 homodimers or monomers may also explain why targeting p19 seems 
more effective than targeting p40 to block the function of IL-23 in the prevention 
of GVHD reported by others52. 
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However, it is worth noting that homodimers and monomeric p40 have not been 
found in humans, indicating neutralization of p40 could possibly be more effective 
in human diseases122. Indeed, our colleagues reported that ustekinumab 
treatment of one patient with advanced, refractory GVHD showed a brief clinical 
remission accompanied by a decrease in IFNγ production and an increase in IL-4 
secretion by whole blood cells stimulated ex vivo with PMA/ionomycin139. In 
addition, ustekinumab has been found to be effective in several Th1/Th17 
mediated human diseases, although the shift toward Th2-differentiation has not 
been observed, such as in psoriasis123,140–142. 
Of clinical importance, we assessed the T cell mediated GVL activity upon 
neutralization of p40 in two preclinical BMT models. When compared with BM 
alone, additional T cells mediated robust anti-tumor effect regardless of anti-p40 
or isotype treatment (Figures 6 and 7), indicating that anti-p40 treatment largely 
preserved GVL activity. The preserved GVL effect could be attributed to the 
maintained total donor T cells (data not shown) and the numbers of IFNγ 
producing donor T cells (Figure 5C) in recipient spleens after anti-p40 treatment. 
Furthermore, a previous study has demonstrated that p40 is not required for the 
CTL function of CD8 T cells in vivo143. Taken together, we concluded that 
inhibition of p40 attenuates GVHD while sparing GVL activity following allo-BMT. 
Considering that both Th1 and Th17 subsets contribute to the development of 
cGVHD, we evaluated the effect of neutralizing p40 on the development of 
cGVHD. We found that anti- p40 treatment significantly improved the clinical 
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manifestations and immune reconstitution without GVHD related mortality (Figure 
8). IL-12 stimulation is critical for DC-mediated priming of naïve CD4 T-cell into 
Tfh144, and subjects deficient for IL-12Rβ1, a receptor for p40, displayed reduced 
circulating Tfh, memory B cells and impaired GC formation85. Consistent with 
this, we found that Tfh generation was reduced with anti-p40 mAb treatment, 
which possibly contributed to the reduced severity of cGVHD. The current study 
agrees with a recent report that anti-p40 treatment attenuates cGVHD in mice145. 
We illustrate that blocking IL-12/23p40 attenuates cGVHD. Paradoxically, a 
previous study shows exogenous IL-12 administration reduces the severity of 
cGVHD in a systemic lupus erythematosus (SLE) model146, in which a large 
numbers of splenocytes from DBA/2 donors were transferred into non-irradiated 
B6D2F1 recipients. There are several differences in these two models: 1) The 
pathophysiology of the SLE cGVHD model is characterized by B-cell hyper-
activation, as well as autoantibody and immune complex-mediated 
glomerulonephritis, in which Th2 cells are the major pathogenic T cells 
contributing to allo- reactive B-cell activation. The mechanism of reducing 
cGVHD by administration of IL-12 in that study was likely because that IL-12 
reduced Th2-differentiation and further inhibited the pathogenesis of allo-reactive 
B cells. On the other hand, sclerodermatous cGVHD model is characterized by 
fibrosis in target organs, which is predominately mediated by activated 
macrophages and Th1/Th17. In the current study, we demonstrate that blocking 
IL-12/23p40 reduces sclerodermatous cGVHD, which is consistent with the 
recent publish by Okamoto, et al.; 2) The pre-conditioning in the two cGVHD 
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models are different. The recipients in the SLE model did not receive any 
irradiation before transplantation, which may affect the contribution of IL-12 in the 
development of cGVHD; 3) IL-12 has been found to have a paradoxical role in 
the development of GVHD82,147. A single injection of IL-12 on the day of BMT 
inhibits aGVHD through Fas-mediated reduction of donor T-cell activation and 
expansion. The dose and timing of IL-12 administration was critical for the 
protective effect, yet only a low dose of IL-12 was protective and administration 1 
hour before BMT was the most efficacious; 4) More importantly, we targeted IL-
12 and IL-23 in combination rather than IL-12 alone. In short, the precise 
mechanisms that account for the discrepancy from the work by Okubo et al. and 
the current work in the context of neutralization are not known and desirable for 
further investigation. 
In conclusion, our study provides strong evidence that both donor- and host-
derived p40 are required for the development of GVHD. Ustekinumab has been 
approved for the treatment of moderate-to-severe psoriasis, and in a Phase 2b 
trial, adults with moderate-to-severe Crohn’s disease resistant to anti-tumor 
necrosis factor treatment showed an increased rate of response to 
ustekinumab148. Our current work provides evidence to support evaluation of p40 
blockade as a potential therapeutic target for the prevention and/or treatment of 




III. IL-23R signaling can bypass IL-12R1 through IL-39 
III.1. Abstract 
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is an effective 
means by which to treat a wide variety of diseases resulting from hematological 
dysfunction. However, the development of graft-versus-host disease (GVHD) 
remains a major cause of morbidity and mortality post transplantation. The IL-12 
family of cytokines is comprised of IL-12, IL-23, IL-27, IL-35, and IL-39. IL-12 family 
members are unique in that each cytokine and cognate receptor is comprised of 
heterodimers in which one subunit is shared among the others. IL-12 (p35+p40) 
and IL-23 (p19+p40) have well documented proinflammatory functions responsible 
for Th1 differentiation and Th17 stabilization, respectively, and play critical roles in 
GVHD development. IL-12R and IL-23R share a β-chain (IL-12Rβ1) yet use 
distinct α-chains to mediate their respective receptor signaling. While both IL-12R 
and IL-23R are widely implicated in inflammatory disorders, the role of IL-12Rβ1 
in this context remains much less defined. We therefore studied the impact of 
eliminating the common IL-12Rβ1 chain or the unique IL-23R chain in T cells on 
GVHD using murine models of allogeneic bone marrow transplantation (BMT). We 
found that donor T cells deficient for IL-12Rβ1 or IL-23R had an abrogated ability 
to cause cGVHD. In agreement with previous publications, we found a pathogenic 
role for IL-23R on donor T cells in aGVHD. Strikingly, a similar effect was not seen 
for IL-12Rβ1. These data suggest that that IL-23R contributes to GVHD 
pathogenesis via a pathway independent of IL-12Rβ1. To confirm that functional 
differences existed between T cells deficient for IL-23R or IL-12Rβ1 in GVHD, we 
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assessed cytokine profiles of these T cells in target organs 14 days post-BMT. We 
found that GM-CSF production by CD4+ T cells was reduced exclusively in T cells 
deficient for IL-23R in the spleen, liver and gut. The newest member of the IL-12 
family, IL-39, has been described to be composed of IL-23p19 and EBI3. Given 
the cognate receptor for IL-39 includes IL-23R and gp130, we hypothesized that 
IL-39 may play a role in aGVHD as this would explain why IL-12Rβ1 is 
dispensable. To validate that p19 and EBI3 can form a heterodimer, we transfected 
SV40 cells with vectors containing control, IL-23p19, EBI3 or both cDNAs.  We 
detected IL-39 heterodimers only in the supernatant of cells transfected with both 
IL-23p19 and EBI3 via ELISA.  Furthermore, we observed significantly increased 
levels of IL-39 in allogeneic recipients at day 14 post BMT compared to recipients 
of BM alone. This may implicate IL-39 in the GVHD development. Taken together, 
our studies indicate that IL-23R plays an essential role, whereas IL-12Rβ1 is 
dispensable, for donor T cells to induce aGVHD, yet that both chains contribute to 
cGVHD. Our proposed model is that in the absence of IL-12Rβ1, IL-39 could 
transmit IL-23Rα signaling, hypothetically by forming a heterodimer with 
gp130. This new finding indicates that IL-23R and IL-39 are potential therapeutic 









Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective means by 
which to treat a wide variety of diseases resulting from dysfunctional 
hematopoiesis; ranging from certain immune deficiencies to severe blood diseases 
and cancers7,13. This therapeutic benefit is primarily due to the donor T cells 
present in the graft, which have the ability to mediate a potent anti-tumor response 
known as the graft-versus-tumor effect (GVT)6. However, donor T cells present in 
the graft also recognize foreign antigens present on host organ tissue, such as the 
skin, lung, GI, and liver, which culminates in the development of graft-versus-host 
disease (GVHD)23. The development of GVHD is second only to primary disease 
as the leading cause of mortality among allo-HCT recipients16. GVHD can occur in 
two phases: acute (aGVHD) and chronic GVHD (cGVHD)18. While aGVHD is 
primarily mediated by mature T cells, cGVHD pathogenesis involves widespread 
autoantibody production by B cells and fibrosis22. In either phase, inflammatory 
cytokines play a critical role in promoting donor T and B cell responses in GVHD. 
 
Currently, the IL-12 family of cytokines is comprised of IL-12, IL-23, IL-27, IL-35 
and, more recently, IL-39149. This family of cytokines is unique in that each 
individual member is heterodimeric, and the individual alpha and beta subunits are 
shared among other members. The shuffling of alpha and beta subunits can lead 
to dramatically different signaling cascades, culminating in a range of pro- to anti-
inflammatory cellular responses39. For example, the alpha cytokine subunit p35 is 
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shared between IL-12, which promotes T helper 1 (Th1) differentiation, and IL-35, 
which is a potently immunosuppressive molecule produced by T regulatory cells 
(Tregs). Similarly, the receptors for IL-12 family members are also heterodimeric 
and bind to their cognate ligand. Briefly, the p19 subunit binds to IL-23R, p35 binds 
to IL-12Rβ2, p28 binds to IL-27R (WSX-1), p40 binds to IL-12Rβ1, and EBI3 binds 
to gp130. Clinically, this property of subunit sharing has been exploited in order to 
target two pathways at once, the best example being ustekinumab, which targets 
the shared p40 subunit of IL-12 and IL-23150. Recent studies have demonstrated 
the requirement of IL-23R expression on pathogenic T cells in various autoimmune 
diseases as well as in aGVHD56,108. While IL-12/23p40 is commonly targeted in 
order to alleviate inflammatory disorders, the contribution of its cognate receptor, 
IL-12/23Rβ1, in T cell-mediated inflammation has not been well defined. 
 
Our studies found that donor splenocytes deficient for IL-23R or IL-12Rβ1 had an 
impaired ability to induce cGVHD compared to WT controls. During cGVHD 
development, both IL-23R and IL-12Rβ1 contributed to thymic damage, as well as 
follicular T cell (Tfh) propagation and IL-21 production, while IL-23R on donor T 
cells played a predominate role in promoting germinal center (GC) B cell activation 
and plasma cell differentiation. Strikingly, a similar effect was not seen for IL-
12Rβ1 across aGVHD models. To explain this, we hypothesized that IL-39 could 
account for these observed disparities in aGVHD. Here, we show that IL-12Rβ1 is 
partially required for aGVHD, and that donor T cells lacking IL-12Rβ1 function 
differently than those completely void of IL-23R signaling. We demonstrate that 
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p19 and EBI3 can form biological heterodimers, and that these heterodimers, 
herein called IL-39, are detectable in the sera of aGVHD recipients. We found IL-
39 levels to be highest at two weeks post BMT in aGVHD, but that IL-39 levels in 
cGVHD were significantly lower at the same time point. Collectively, we provide 
evidence that IL-39 levels are increased in aGVHD, but not in cGVHD models, 
providing a potential explanation for why GVHD progression may be observed in 
the absence of IL-12Rβ1 in aGVHD. In cGVHD, both IL-23R and IL-12Rβ1 
contribute to disease pathogenesis and are viable targets in clinical scenarios. We 
interpret that donor T cells have a differential requirement for IL-12Rβ1 or IL-23R, 
which is dependent on the level of histocompatibility antigen mismatch and/or 
degree of inflammation (e.g. acute vs chronic phase) in GVHD. 
 
III.2. Materials and methods 
III.2.a. Mice 
C57BL/6 (B6; H-2b), B6.Ly5.1 (H-2b), BALB/b (H2b), BALB/c (H2d), B6D2F1(B6 
x DBA2) (H2b/d) mice were purchased from the National Cancer Institute/National 
Institute of Health. IL-12Rβ1KO mice were purchased from Jackson labs and IL-
23Rnull mice were provided by Dr. Benny Yang. All animals were housed at the 
American Association for Laboratory Animal Care–accredited Animal Resource 
Center at the Medical University of South Carolina. All mice were treated in 
adherence to the NIH Guide for the Care and Use of Laboratory Animals and their 
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respective protocols approved by local Institutional Animal Care and Use 
Committees. 
III.2.b. Murine GVHD models 
Recipient mice were lethally irradiated at 700 cGy for BALB/c and 1000-1200 cGy 
(2 split doses, 3-hour interval) for B6D2F1 recipient mice using an X-RAD 320 
irradiator (Precision X-Ray). Within 24 hours of irradiation, Balb/c or B6D2F1 
recipient mice were transplanted with 5.0×106 T cell depleted bone marrow cells 
(TCD-BM) from B6 donors with or without T cells (0.5–1×106/mouse). Recipient 
survival was monitored throughout the experiment. Body weight loss was 
monitored twice per week and clinical signs of GVHD were monitored once per 
week and include posture, skin damage, hair loss, ruffled fur, diarrhea, and 
decreased activity. 
III.2.c. Transfected Cell Lines 
SV40 cells were transfected with vectors (Sino Biological) containing control, IL-
23p19, EBI3 or both cDNAs according to the manufacturer’s instructions 
(lipofectamine 3000). 
III.2.d. Flow cytometry  
Mononuclear cells were isolated from mouse recipient spleen or liver. Live/dead 
fixable yellow from Invitrogen (cat # L34968) was used to distinguish live and dead 
cells.  To measure intracellular cytokines, cells were stimulated for 4–5 h at 37°C 
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with PMA (100 ng/ml, Sigma-Aldrich) and ionomycin (100 ng/mL; Calbiochem, 
EMD) in the presence of GolgiStop (BD Biosciences). Fix and permeabilization 
were performed using Cytofix/Cytoperm Plus (BD Biosciences). Stained cells were 
analyzed using FACSDiva software, LSR II (BD Biosciences, San Jose, CA), and 
FlowJo (Tree Star, Ashland, OR). The following antibodies were used for cell-
surface staining: anti-CD4–V450 (RM4-5), -APC, and -PEcy7 (BD Biosciences), 
anti–CD8-PEcy5 (53-6.7), -APCcy7 and -AF700 (BD Biosciences,); anti-CD45.1-
FITC (A20), - and -APC (BD Biosciences),   anti-B220-FITC (RA3-682) and -PE 
(eBioscience), anti-CD44–APC,PE(eBioscience,) (IM7) anti-CD62L-Pecy5,-
FITC(eBioscience) (MEL-14),CD25–FITC (7D4) ,Pecy7 (eBioscience) (PC 61.5) 
and anti-H2Kb (AF6-88.5.5.3). Intracellular staining was carried out using anti-IFN-
γ-PE or Per-cp 5.5 (XMG1.2; BD Biosciences), anti-IL-4-PE (11B11; BD 
Pharmingen), anti–IL-5–PE (TRFK5; BD Pharmingen), anti-Foxp3-PE (FJK-16s; 
eBioscience). 
III.2.e. Enzyme Linked Immunosorbent Assay (ELISA) 
ELISA plates (Costar) were coated with anti-p19 (5B2; ebioscience) and incubated 
overnight at 4oC. Plates were washed 4 times with 0.1% Tween 20 in PBS, blocked 
with 1% BSA for 1hr, then serum samples (1:5 dilution) or supernatant (1:5 dilution) 
were added to wells and incubated overnight at 4oC. Plates were washed 4 times 
with 0.1% Tween 20 in PBS and incubated with biotinylated anti-EBI3 (210-306-
C55; Rockland) for 1hr at room temperature. Plates were washed again as 
previously described and incubated for 1hr with streptavidin (18-4100-94; 
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ebioscience). After washing, TMB substrate (00-4201-56; Invitrogen) was added 
and incubated for 10-30 minutes at room temperature. Reaction was stopped by 
adding 1M H3PO4. 
III.2.f. Immunoblots/ Immunoprecipitation 
SV40 cells were transfected as described. Transfected cells were harvested and 
lysed in 1% Triton-X lysis buffer for 60 minutes. After lysis, samples were 
centrifuged and soluble fractions were separated from non-soluble fractions, boiled 
in laemmli buffer, then probed for gp130 (Cell signaling; 3732S) or IL-23R (RnD; 
AF1689) using western blot. For cytokine immunoprecipitation, supernatant from 
transfected cells was probed for p19 (RnD;) and immunoblotted for EBI3 
(Rockland).  
III.2.g. Statistics 
For comparisons of independent murine data, the 2-tailed Student’s t-test was 
used. The Mann-Whitney test was used for comparisons of nonparametric data. 









III.3.a. IL-12Rβ1 and IL-23R are required for cGVHD development 
Given that IL-12R and IL-23R share a common receptor subunit, IL-12Rβ1, our 
initial studies focused on whether this was as important for GVHD pathogenesis 
as its ligand, IL-12/23p40. To investigate the role individual IL-12Rβ1 or IL-23Rα 
on T-cell activation and pathogenicity, we utilized IL-12Rβ1 knock-out (KO) and IL-
23Rα functional inactive mice (refer as KO hereafter for simplicity)151. 
Immunological phenotypes of either strain of mice showed no significant 
differences in CD4 or CD8 memory frequency, B cells, or Tregs as compared with 
WT counterparts. Recent data has demonstrated that blocking p40 alleviates 
cGVHD150,152. cGVHD can affect more than 50% of patients and is the primary 
long-term cause of morbidity after allo-HCT31.  Furthermore, both donor T and B 
cells contribute to cGVHD pathogenesis and both express IL-12Rβ1 and IL-
23Rα35,36,43,108.  Therefore, we first endeavored to define the roles of IL-12Rβ1 and 
IL-23R on cGVHD using a major MHC-mismatch B6 to BALB/c model. 
Interestingly, cGVHD development was observed to depend on both IL-12Rβ1 and 
IL-23R (Figure 1A,B). To confirm this, we also utilized a B6 to B6D2F1 cGVHD 
model, in which we observed consistent results (Figure 1C,D). Pathological 
analyses on target organs at multiple time-points supported reductions in cGVHD 
of the recipients deficient for either receptor unit (Figure 1E).  
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Figure 1. IL-23Rα and IL-12Rβ1 contribute to cGVHD. Lethally irradiated BALB/c (A, B) or 
B6D2F1 (C, D) mice were transplanted with 5x106 TCD-BM alone or plus 0.35x106 whole 
splenocytes (BALB/c) or 2.5x106 purified T cells (B6D2F1) from WT B6, IL-12R𝛃1KO, or IL-
23RαKO mice; donor grafts containing TCD-BM and splenocytes/ T cells were matched based on 
genetic background.  Survival and clinical score of BALB/c (A, B) and B6D2F1 (C, D) are shown. 
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Since cGVHD pathogenesis involves thymic damage, as well as a much broader 
array of cellular subsets such as B cells and T follicular helper (Tfh) cells, we 
hypothesized that IL-12Rβ1 may be important for B cell activation or Tfh 
differentiation. Because BM derived cells also contribute to cGVHD, we initially 
examined cGVHD development when both BM and splenocytes were the donors 
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deficient for IL-12Rβ1 or IL-23R. At 60 days post allo-HCT, we evaluated B cell 
reconstitution and T cell differentiation (Figure 2). Both CD4 and CD8 Tfh 
(CXCR5+PD1+) differentiation were reduced (Figure 2A,B), while Tfr 
(CD4+CXCR5+PD1+Foxp3+) differentiation was increased in IL-12Rβ1KO and IL-
23RKO recipients (Figure 2C,D). While B cell reconstitution was significantly 
improved in recipients of IL-12Rβ1 or IL-23R deficient donor grafts (Figure 2E,F), 
we found that plasma cell differentiation was reduced only in IL-23RKO recipients 
(Figure 2G,H). However, germinal center B cells were significantly reduced in both 
cohorts at day 60 versus WT controls (Figure 2I,J). IFNγ production was 
significantly decreased in both IL-12Rβ1KO and IL-23RKO recipients, while IL-17 
was reduced only in IL-23RKO cohorts, and IL-21 was reduced only in IL-
12Rβ1KO cohorts (Figure 2K,L). Collectively, both IL-12Rβ1 and IL-23R contribute 
to cGVHD development.  
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Figure 2. Similar effect of IL-23Rα and IL-12Rβ1 in cGVHD. Lethally irradiated BALB/c mice 
were transplanted with 5x106 TCD-BM alone or plus 0.35x106 whole splenocytes from WT B6, IL-
12R𝛃1KO, or IL-23RαKO mice. At 60 days post BMT, remaining mice were sacrificed, and 
spleens were taken for analysis by flow cytometry. Representative frequencies of 
H2Kb+CD4+CXCR5+PD1+ (A, top), H2Kb+CD8+CXCR5+PD1+ (A, bottom), as well as graphical 
depictions (B), are shown.   A ratio of Foxp3+:Foxp3-  among H2Kb+CD4+CXCR5+PD1+Foxp3+ 
cells (C) and associated graphical data (D) is shown. Representative frequencies of donor B cells 
(E), plasma B cells (G) and germinal center B cells (I) and associated graphical summaries (F, H, 
J) are shown. Representative frequencies of donor CD4+ T cell production of IFN (K, top), IL-17 
(K, middle) and IL-21 (K, bottom), as well as graphical summaries (L) for CD4 (left) and CD8 


























































































































































































































III.3.b. IL-12Rβ1 and IL-23R differentially impact cGVHD development  
While our data at day 60 post-transplant (Figure 2) was consistent with the notion 
that both IL-12Rβ1 and IL-23Rα are essential for cGVHD, we observed 
discrepancies in the function of these receptors on donor splenocytes, for example, 
in the context of plasma B cell differentiation which was heavily affected by IL-
23Rα (Figure 2A,B). We then tested whether using WT BM had any impact on 
outcomes when transplanted with receptor deficient splenocytes and found that it 
did not. To determine potential mechanisms for the role of IL-12Rβ1 and/or IL-
23Rα during cGVHD development, we utilized CD45.1+ BM to evaluate how these 
receptors on donor splenocytes affected thymus reconstitution (Figure 3) at days 
14, 30, and 45. Thymus reconstitution was notably improved in cohorts receiving 
IL-23Rα deficient splenocytes at earlier time points, yet comparable effects were 
observed in cohorts that received IL-12Rβ1KO splenocytes by day 45 (Figure 
3A,B). Absolute numbers of double positive (DP) thymocytes were consistently 
improved (Figure 3C). Notably, in the single positive (CD4+ or CD8+) populations, 
there were significant reductions in frequencies of non-BM derived donor T cells 
(Figure 3D-F), suggesting that both IL-12Rβ1 and IL-23Rα were required for 
thymus infiltration.  We also examined the spleen and peripheral lymph nodes 
(pLN) at days 14, 30, and 45. In the Tfh compartment, CD4+CXCR5+PD1+ T cells 
were significantly reduced in cohorts that received IL-12Rβ1KO splenocytes, while 
CD8+CXCR5+PD1+ T cells were significantly reduced in the recipients of either 
IL-12Rβ1KO or IL-23RαKO graft as compared to those of WT graft (Figure 4). This 
decrease in CD4+CXCR5+PD1+ correlated with Bcl6 expression, the 
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transcriptional regulator of Tfh differentiation, in recipients of either IL-12Rβ1KO or 
IL-23RαKO splenocytes at day 45 (Figure 4A-C). As the main effector cytokine of 
Tfh cell is IL-21, we measured and  found that WT controls produced significantly 
more IL-21 from CD4+ T cells at days 30 and 45 than either KO cohorts in recipient 
spleen; similar results were observed on CD8+ cells at day 45 (Figure 4D). 
Analysis of the pLN revealed reductions in CD4+ IL-21 for IL-23RKO cohorts at 
days 30 and 45, IL-12Rβ1KO exhibited similar reductions at day 45 (Figure 4E). 
Interestingly, B cell differentiation and activation was significantly reduced in 
cohorts that received IL-23RKO splenocytes, as indicated by stagnant GC 
development, plasma cell differentiation, and CD86 expression at days 30 and 45, 
which was not observed in IL-12Rβ1KO cohorts (Figure 4 F-I). In general, IL-
12Rβ1 or IL-23RKO donor T cells produced lower levels of IFNγ or IL-17, 
respectively, in both the spleen and pLN. However, IL-4 production was 
significantly increased in IL-12Rβ1KO T cells at day 30 in the spleen and lymph 
nodes while the opposite trend was seen for IL-23RKO T cells. Collectively, both 
IL-12Rβ1 and IL-23R contribute to thymic damage and Tfh differentiation, yet IL-
23R may play a predominant role vs IL-12Rβ1 in regulating donor T cell 




Figure 3. IL-23Rα and IL-12Rβ1 inhibit thymus reconstitution. Lethally irradiated BALB/c mice 
were transplanted with 5x106 WT B6Ly5.1+ alone or plus 0.35x106 whole splenocytes from WT 
B6, IL-12R𝛃1KO, or IL-23RαKO mice. Thymus was collected from mice 14, 30, and 45 days post-
BMT. Flow cytometry depictions of double positive (CD4+CD8+) from the thymus at day 14 (A) 
and graphical representations of double positive (CD4+CD8+) frequencies (B), absolute number of 
double positive (CD4+CD8+) cells (C), as well as single positive for CD4 (D) or CD8 (E) non-BM 




=6-8. *p<0.05, **p<0.01, 
***p<0.001 
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Figure 4. IL-23Rα and IL-12Rβ1 promote Tfh/B cell responses. Lethally irradiated BALB/c 
mice were transplanted with 5x106 WT B6Ly5.1+ alone or plus 0.35x106 whole splenocytes from 
WT B6, IL-12R𝛃1KO, or IL-23RαKO mice. Spleen was collected from mice 14, 30, and 45 days 
post-BMT. Frequency of BCL6 from gated CD4+ cells at day 45 (A) and graphical depictions of 
CD4+ (B, top) and CD8+ (B, bottom) CXCR5+PD1+, BCL6, and IL-21 in the spleen (left to right) 
over time are shown. (C) IL-21 production by CD4 (top) and CD8 (bottom) in the peripheral LNs 
over time are shown. (D) Graphical depictions of frequencies of donor B cells, plasma cells, 

























































































































































































III.3.c. IL-23R signaling can mediate aGVHD in the absence of IL-12Rβ1 
We then focused on the role of IL-23R and IL-12Rβ1 in aGVHD. Initial studies to 
characterize T cell responses were focused on proliferation and cytokine 
production after being adoptively transferred into allogeneic recipients. We 
observed similar reductions in IL-23R and IL-12Rβ1 deficient donor T cells 
compared to WT controls in terms of IFN, IL-17 or GM-CSF production. Therefore, 
we hypothesized that IL-23R and IL-12Rβ1 would contribute to aGVHD. To test 
this, we used 3 murine models of allo-HCT: B6 to BALB/b (miHA mismatch), B6 to 
B6D2F1 (haploidentical mismatch), and B6 to BALB/c (complete mismatch).  In 
the miHA model, we observed improvements in survival among recipients of IL-
23R and IL-12Rβ1 deficient donor T cells compared to WT controls, although 
clinical scores were significantly reduced only in recipients of IL-23RKO T cells. 
Experiments using haploidentical recipients also yielded improvements in survival 
versus WT, yet recipients of IL-23RKO T cells also had significantly better survival 
than recipients of IL-12Rβ1KO T cells (Figure 5C). However, in complete mismatch 
models, outcomes in recipients of IL-12Rβ1KO T cells showed no improvements 
compared to WT controls, while recipients of IL-23RKO T cells also had 
significantly improved survival and clinical scores (Figure 5E,F).  In fact, no 
significant differences were observed when donor T cells lacked IL-12Rβ2 or IL-
12Rβ1 compared to WT controls in the B6 to BALB/c model. This data indicates a 
dominant role for IL-23R in minor-, haplo-, and major-mismatch GVHD models, 
and the differences correlated with degree of MHC-mismatch (Figure 5 A-F).  
 58 
 
Figure 5. Effect of IL-12R𝛃1 and IL-23Rα in aGVHD. Lethally irradiated BALB/b (A, B), B6D2F1 
(C, D) or BALB/c (E,F) mice were transplanted with 5x106 TCD-BM alone or plus 1x106 (BALB/c), 
3x106 CD25- (B6D2F1), or 3x106 (BALB/b) purified T cells from WT B6, IL-12R𝛃1KO, or IL-23RαKO 
mice.  Survival (A, C, E) and clinical score (B, D, F) of BALB/b (left), B6D2F1 (middle), and BALB/c 
recipients (right) are shown.  Data shown is pooled from 2-4 replicate experiments with a total of 
15-30 mice per group. *p<0.05, **p<0.01, ***p<0.001 
 
 
To further evaluate the role of IL-23R in GVHD development, we blocked IL-23R 
using a commercially available antibody and found that the treatment with anti-IL-
23R significantly improved recipient survival and clinical scores compared to with 
vehicle control. Together, these data show that IL-23R signaling is required for 
donor T cells to induce aGVHD, and that this requirement is positively correlated 
with the degree of histocompatibility disparity among donor and recipients. 
Furthermore, these data indicate that IL-23R signaling may be able to bypass IL-
12Rβ1 in certain scenarios. 
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III.3.d. IL-23R and IL-12Rβ1 are functionally different on donor T cells during 
aGVHD 
We then sought to determine how IL-12Rβ1 and IL-23R differentially impacted the 
donor T cell response in the context of aGVHD. We utilized the B6 to BALB/c 
model, as we had observed the most significant differences in survival and clinical 
score (Figure 5 A,B). Hence, we assessed cytokine profiles of T cells in target 
organs 14 days post-BMT.  While production of IFNγ and IL-17 of donor T cells in 
recipient spleen was similarly decreased in both cohorts, GM-CSF production by 
CD4+ T cells was reduced exclusively in T cells deficient for IL-23R (Figure 6). 
Further, a significant reduction of IFNγ and GM-CSF in target organs, such as the 
liver (Figure 6A,B) and gut (Figure 6C), was only observed in T cells deficient for 
IL-23R. We also observed stark increases in GM-CSF production in IL-12Rβ1, but 
not IL-23R, deficient T cells in the spleen (Figure 6E). Albeit, this data suggests 
that IL-23R signaling promotes GM-CSF production by donor T cells which occurs 
independently of IL-12Rβ1. 
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Figure 6: IL-23Rα regulates GM-CSF production in aGVHD. Lethally irradiated BALB/c mice 
were transplanted with 5x106 TCD-BM alone or plus 0.75x106 purified T cells from WT B6, IL-
12R𝛃1KO, or IL-23RαKO mice. Lymphocytes were isolated from the liver (A, B), gut (C) and 
spleen (D) of mice 14 days post-BMT. (A) Frequencies of donor CD4+ and CD8+ IFN𝜸, IL-17 and 
GM-CSF (left to right) as well as graphical representations (B) from the liver, gut (C), and spleen 
(D) are shown *p<0.05, **p<0.01, ***p<0.001 
 
 
III.3.e. p19 and EBI3 heterodimers are detectable in aGVHD 
The newest member of the IL-12 family, IL-39, was recently shown to contribute to 
SLE pathogenesis; this cytokine has been described to be composed of IL-23p19 
and EBI3110. Given the cognate receptor for IL-39 includes IL-23Rα and gp130, we 
hypothesized that IL-39 may play a role in aGVHD as this would explain why IL-












































































































































































a heterodimer, we transfected SV40 cells with vectors containing control, IL-23p19, 
EBI3 or both cDNAs.  Antibody specificity for both p19 and EBI3 correlated with 
transfected subunits in the supernatant of SV40 cells (Figure 7A,B). We detected 
IL-39 heterodimers only in the supernatant of cells transfected with both IL-23p19 
and EBI3 via ELISA (Figure 7C). Heterodimer formation was confirmed with 
immunoprecipitation experiments (Figure 7D). Given that differences between IL-
12Rβ1 and IL-23R seemed to correlate with the degree of histocompatibility 
antigen disparity in aGVHD models, together with the fact that both receptors 
played a role in cGVHD, we hypothesized that IL-39 would be increased in aGVHD 
compared to cGVHD. To test this, we used ELISA to measure serum IL-39 at 
various time points in aGVHD and cGVHD (Figure 7E). We observed significantly 
increased levels of IL-39 in allogeneic recipients at day 14 post BMT in aGVHD 
compared to the recipients of BM alone. This trend of higher IL-39 in aGVHD 
continued at later time points, but mortality in the aGVHD setting prevented our 
ability to adequately evaluate significance. In contrast, we did find elevated IL-39 
levels in sera from the recipients with cGVHD as compared to those from the 
recipients of BM alone in any time-point tested (data not shown). Taken together, 
the data implicates IL-39 in aGVHD development and could serve as one 
explanation for why IL-12Rβ1 is dispensable in certain scenarios. 
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Figure 7: p19 and EBI3 form heterodimers that are detectable in aGVHD. SV40 cells were 
transfected with vectors containing control, IL-23p19, EBI3 or both cDNAs. After 2 days, 
supernatant was harvested and ELISA was performed for (A) p19, (B) EBI3 or (C) p19/EBI3 
heterodimers. (D) Supernatant from transfected SV40 cells was TCA precipitated (input) or 
immunoprecipitated with anti-p19 and probed by western blot for EBI3 (top) and p19 (bottom). 
Recipient Balb/C mice were lethally irradiated and transplanted with 5x106 TCD-BM alone or plus 
0.75x106 purified T cells (acute GVHD) or 0.35x106 whole splenocytes (chronic GVHD) from B6 
mice. ELISA for IL-39 was performed as previously described using serum taken at days 7 


















































































































The current study indicates that both IL-23R and IL-12Rβ1 play a role in cGVHD, 
whereas IL-12Rβ1 is dispensable for donor T cells to induce aGVHD; potentially 
due to IL-39, a novel cytokine in the allo-HCT field. The contribution of p40 to 
cGVHD has been shown. However, to our knowledge, these are the first studies 
evaluating the effect of IL-23R and IL-12Rβ1 in cGVHD.  
 
In cGVHD, thymic damage by donor T cells was abrogated in the absence of either 
receptor chain, leading to improvements in thymus reconstitution, especially in 
recipients of IL-23RKO splenocytes at early time points. IL-23 has been shown to 
promote RORγt-dependent apoptosis in DP thymocytes, which may explain the 
accumulation of DP thymocytes in recipients of IL-23R and IL-12Rβ1 deficient 
splenocytes153. Interestingly, studies in lupus models found that IL-23p19KO mice 
developed less SLE than WT controls via influencing thymic selection, indicating 
that IL-23 may promote pathogenic T cell development in the thymus during 
cGVHD154.  
 
Additionally, IL-23R and IL-12Rβ1 both had a significant impact on Tfh 
differentiation during cGVHD development in our models, which culminated in 
similar reductions in BCL6 expression and IL-21 production by CD4+ T cells at day 
45 post- BMT in the spleen and lymph nodes. However, recent reports by others 
in the field suggest that CXCR5 and PD1 alone may not be sufficient to distinguish 
Tfh cells35. Albeit, we did find that the master transcription factor of Tfh cells, BCL6, 
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had a correlated reduction with CXCR5+PD1+ cells in the spleen. Importantly, IL-
12 and IL-23 have both been shown to contribute to Tfh development and function 
in humans155.  Lastly, B cell differentiation and activation was profoundly affected 
by IL-23R expression on donor splenocytes, but not by IL-12Rβ1, indicating a 
potential requirement for IL-23R signaling to induce inflammatory stimulation of B 
cells in cGVHD. Studies using lupus models have indicated that IL-23 signaling is 
critical for SLE development not only by promoting pathogenic T cell responses 
but also by enhancing B cell responses and autoantibody production156. Consistent 
with this, we found significantly lower frequencies of plasma cells in cohorts that 
received IL-23R deficient grafts. Germinal center formation is known to be 
preceded by Bcl-6 expression in CD4+ T cells. We found that, although not 
significantly different at earlier time points, IL-23R deficient donor T cells had a 
notable trend of less Bcl6 expression over time, which could possibly explain the 
dramatic reductions in GC formation compared to WT controls. 
 
We found a pathogenic role for IL-23R on donor T cells in aGVHD, yet a similar 
effect was not seen for IL-12Rβ1. At baseline, these data suggest that that IL-23R 
may contribute to GVHD pathogenesis via a pathway independent of IL-12Rβ1. 
We found that GM-CSF production by CD4+ T cells was reduced exclusively in T 
cells deficient for IL-23R. Further, a significant reduction of IFNγ and GM-CSF in 
target organs, such as the liver and gut, was only observed in T cells deficient for 
IL-23R. This indicates that IL-23R may play a direct role in promoting GM-CSF 
production by donor T cells. As GM-CSF was recently shown to license DC and 
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macrophage production of proinflammatory mediators such as IL-1β, this may be 
a contributing factor to differences observed between cohorts receiving IL-
12Rβ1KO or IL-23RKO T cells. Recent publications support the notion that GM-
CSF is critical, especially in the gut, for GVHD development157. However, these 
studies on GM-CSF focus primarily on aGVHD (versus cGVHD), hence we did not 
check GM-CSF in our cGVHD models. Thus, we cannot rule out a role for GM-
CSF in cGVHD; as both receptor chains were important for cGVHD, the impact of 
GM-CSF may be less vital in our studies. More research is required on this point. 
Given the cognate receptor for IL-39 includes IL-23Rα and gp130, we 
hypothesized that IL-39 may play a role in aGVHD as this would explain why IL-
12Rβ1 is dispensable. We detected IL-39 heterodimers only in the supernatant of 
cells transfected with both IL-23p19 and EBI3 via ELISA and we observed 
significantly increased levels of IL-39 in allogeneic recipients at day 14 post BMT 
compared to cGVHD mice or recipients of BM alone. While our finding is novel in 
the field, many questions still remain regarding the role of IL-39 in GVHD. IL-39 
was originally identified in lupus models and found to be produced by B cells110. 
However, aGVHD is primarily T cell mediated, leaving a large pool of cells that 
may potentially produce IL-39. Studies to identify these cells are ongoing. 
Importantly, the translational impact of IL-39 has yet to be validated as it has not 
been observed in humans. Hence, the most critical question we are focused on is 
detecting this cytokine in patient samples. Our proposed model is that in the 
absence of IL-12Rβ1, IL-39 could transmit IL-23R signaling by forming a 
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heterodimer with gp130. This new finding indicates that IL-23R and IL-39 may 




































IV. Targeting JAK2 reduces GVHD and xenograft rejection through 
regulation of T cell differentiation 
 
IV.1. Abstract 
Janus kinase 2 (JAK2) signal transduction is a critical mediator of the immune 
response. JAK2 is implicated in the onset of graft-versus-host disease (GVHD), 
which is a significant cause of transplant-related mortality after allogeneic 
hematopoietic cell transplantation (allo- HCT). Transfer of JAK2−/− donor T cells 
to allogeneic recipients leads to attenuated GVHD yet maintains graft-versus-
leukemia. Th1 differentiation among JAK2−/− T cells is significantly decreased 
compared with wild-type controls. Conversely, iTreg and Th2 polarization is 
significantly increased among JAK2−/− T cells. Pacritinib is a multikinase inhibitor 
with potent activity against JAK2. Pacritinib significantly reduces GVHD and 
xenogeneic skin graft rejection in distinct rodent models and maintains donor 
antitumor immunity. Moreover, pacritinib spares iTregs and polarizes Th2 
responses as observed among JAK2−/− T cells. Collectively, these data clearly 
identify JAK2 as a therapeutic target to control donor alloreactivity and promote 
iTreg responses after allo-HCT or solid organ transplantation. As such, a phase I/II 
acute GVHD prevention trial combining pacritinib with standard immune 









Janus kinase 2 (JAK2) signal transduction is implicated in human autoimmune 
syndromes158,159 and graft-versus-host disease26,160,161.  IL-6, IL-12, and IL-23 
mediate inflammation and activate T cells via JAK225,160,161.  IL-6 receptor blockade 
has demonstrated efficacy in a phase II GVHD prevention trial162, but does not fully 
impair pathogenic Th1/Th17 responses163.  IL-12 and IL-23 promote Th1 and Th17 
differentiation, respectively, via JAK2159. Neutralizing the shared p40 subunit of 
these cytokines prevents GVHD in rodents152 and may have merit in treating 
patients with steroid refractory GVHD139.  
 
JAK2 inhibition is an alternative approach to suppress IL-6 and p40 receptor signal 
transduction and induce durable tolerance to alloantigens160.  JAK2 inhibitors are 
clinically efficacious in myelofibrosis, a disease often driven by constitutive JAK2 
activation164.  The existing evidence regarding JAK2 as a therapeutic target for 
acute GVHD is primarily supported by observations using ruxolitinib, an equimolar 
inhibitor of JAK1 and JAK2161,165–168.  Ruxolitinib has demonstrated efficacy in 
treating steroid-refractory GVHD, yet is immune suppressive161,165.  In part, JAK1 
mediates the biologic effects of common gamma chain cytokines, including IL-2 
and IL-15160.  Ruxolitinib suppresses host-reactive T cells in mice161,166–168 and 
humans161,165.  Although not observed in murine transplant studies, ruxolitinib 
reduces the quantity of human Tregs169 and NK cells170,171.  Therefore, targeting 
JAK2 has the potential to prevent GVHD without conceding JAK1-mediated 
functions provided by donor lymphocytes.  
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We report that genetic deletion or pharmacologic inhibition of JAK2 significantly 
reduces GVHD lethality and spares the GVL effect.  Moreover, we demonstrate 
that JAK2 blockade significantly delays skin graft rejection.  We have shown that 
JAK2 blockade abrogates human Th1 and Th17 responses using TG10134826,172.  
TG101348 is now regarded as a tool compound, as its use was associated with 
Wernicke encephalopathy caused by off-target inhibition of thiamine uptake173.  
Therefore, we investigated the use of pacritinib, a JAK2 inhibitor that does not 
impair thiamine metabolism174.  Distinct from ruxolitinib, pacritinib spares JAK1 
activity required by anti-tumor cytotoxic T lymphocytes and Tregs175.  Here, we 
identify that eliminating JAK2 signal transduction significantly enhances Th2 and 
Treg differentiation while dramatically reducing Th1 responses.  Thus, we prove 
that JAK2 inhibition significantly suppresses donor T cells across species without 












IV.3. Materials and Methods 
 
IV.3.a. Mice 
C57BL/6 (B6; H-2b), B6.Ly5.1 (H-2b), BALB/b (H2b), BALB/c (H2d), and (B6 x 
DBA2)F1 (H2b/d) mice were purchased from the National Cancer 
Institute/National Institute of Health. Mice with a conditional KO of JAK2 on the T 
cell lineage were generated by breeding JAK2fl/fl (provided by Dr. Wagner at 
University of Nebraska) with CD4-Cre (purchased from Taconic).  NOD-scid 
gamma-deficient (NSG) mice were purchased from Jackson Laboratory (Bar 
Harbor, ME, USA).  With exception to the NSG mice who were housed at the 
Moffitt Cancer Center, all other animals were housed at the American 
Association for Laboratory Animal Care–accredited Animal Resource Center at 
Medical University of South Carolina.  All mice were treated in adherence to the 
NIH Guide for the Care and Use of Laboratory Animals and their respective 
protocols approved by local Institutional Animal Care and Use Committees. 
 
IV.3.b. Murine GVHD and Bioluminescent Imaging (BLI) 
Lethally irradiated BALB/c (MHC-mismatched) or BALB/b (MHC-matched, minor 
histocompatibility antigen-mismatched) mice received 5x106 TCD-BM alone or 
plus 1x106 (BALB/c) or 3x106 (BALB/b) T cells from WT B6 or JAK2 KO mice.  
Recipient body weight and survival was assessed twice weekly.  GVHD 
pathology scores were assessed in a blinded fashion by an independent 
pathologist.  Where indicated, B6.Ly5.1+ TCD-BM and B6.Ly5.2+ WT and JAK2 
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KO T cells were used.  For GVL experiments, BALB/c recipients received TCD-
BM alone, TCD-BM with 2×103 luciferase-transduced A20, or TCD-BM plus WT 
B6 or JAK2 KO T cells and luciferase-transduced A20.  (B6 x DBA2)F1 mice 
received TCD-BM alone, TCD-BM with 5x103 luciferase-transduced P815 tumor 
cells, or 3x106 WT B6 T cells and luciferase-transduced P815 tumor cells.  BLI 
was performed as previously described25.  As indicated, pacritinib or its vehicle 
control were administered at 25-100mg/kg by oral gavage daily from day 0 for 3 
weeks after BMT.  Where indicated, ruxolitinib (a JAK1/2 inhibitor control) was 
given at 30mg/kg twice a day by oral gavage. 
 
IV.3.c. Xenograft model 
NSG mice (male or female, 6-24 weeks old) received a 1cm2 split thickness 
human skin graft under anesthesia.  Eligible patients undergoing mastectomy 
were consented and skin was collected in accordance with an IRB-approved 
protocol at Moffitt Cancer Center (MCC 17634).  The bandage and sutures were 
removed after 7-10 days.  Thirty days later, recipient mice then received 5x106 
fresh, human PBMCs (OneBlood) i.p. using a random donor allogeneic to the 
skin graft172,176.  Each transplant experiment used a unique donor pair of skin and 
PBMCs.  Pacritinib 100mg/kg or vehicle was given by oral gavage twice a day 
from day 0 until day +14.  The skin grafts were followed closely for signs of 
rejection, such as ulceration, necrosis, or scabbing.  Skin grafts that were >75% 
non-viable were considered rejected.  Pathologic skin rejection grading was 
performed according to criteria set forth by Bejarano and colleagues177.  Tissue 
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samples were prepared, stained (Ventana Medical Systems, Tucson, AZ), and 
imaged (Vista, CA, USA) as previously described26.   
 
IV.3.d. Statistics 
For comparisons of independent murine data, the 2-tailed Student’s t-test was 
used.  For comparisons of dependent human data, the 2-tailed paired t-test was 
used.  The Mann-Whitney test was used for comparisons of nonparametric data.  
ANOVA was used for group comparisons.  The log-rank test was used to analyze 
GVHD and skin graft survival. 
 
IV.4. Results 
IV.4.a. JAK2 signaling promotes Th1 differentiation, but inhibits Th2- and 
Treg-responses by allo-activation in vitro  
To examine the effect of JAK2 in T cells, we employed mice in which JAK2 is 
conditionally deleted in T cells(JAK2flox/flox x CD4- Cre).  Phenotypically, the 
frequency of splenic CD4+ T cells among JAK2-/- mice was decreased compared 
to that of naive B6 mice (Supplemental Figure 1 A, D), though proportions of CD8+ 
T cells and CD4+ Tregs were similar (Supplemental Figure 1 A, B, D, E).  The 
composition of T cell subsets within the naïve and central memory compartments 
were also similar between JAK2-/- and WT mice (Supplemental Figure 1 C, F,G); 
with only a subtle increase in CD8+ effector memory T cells in JAK2-/-  mice 
(Supplemental Figure 1 G).  In response to alloantigen stimulation, proliferating 
(CFSElow) JAK2-/- CD4+ and CD8+ T cells produced significantly less IFNγ, yet 
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higher levels of IL-4/5 and IL-10 compared to WT T cells (Supplemental Figure 2A, 
B).  These data indicate that JAK2 signaling is critical for Th1 differentiation, and 
opposes Th2 and Treg development after alloantigen stimulation in vitro.  
 
JAK2 contributes to T cell-mediated GVHD, but is dispensable for the GVL effect 
To study how JAK2 affects donor T cell responses to alloantigen in vivo, we first 
evaluated GVHD severity after transfer of JAK2-/- or WT T cells to major MHC-
mismatched recipients.  JAK2-/-  T cells had a significantly reduced ability to induce 
lethal GVHD compared to WT T cells (Figure 1A, B).  Furthermore, a consistent 
reduction in GVHD severity was e observed in a minor MHC-mismatch model of 
BMT (Figure 1C, D). Impaired immune reconstitution is associated with GVHD178. 
We therefore examined donor–derived T and B cell reconstitution in surviving 
BALB/c recipients 80 days post BMT.  In the thymus, the percentage and absolute 
number of double positive thymocytes (CD4+CD8+) were comparable to cohorts 
receiving TCD-BM only (Supplemental Figure 3A and B).  In the spleen, the 
absolute numbers of CD4+ T cells and B cells in recipients of JAK2-/- T cells were 
reduced compared to those of TCD-BM alone (Supplemental Figure 3B); the 
frequencies of donor-derived CD4+ and CD8+ T cells, and of B cells were 
comparable (Supplemental Figure 3A).  These data indicate that JAK2 signaling in 
T cells facilitates recipient thymic damage typically associated with GVHD(22), yet 
may enhance peripheral T and B cell counts after allo-HCT.  
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In studies examining the effect of JAK2 on GVL activity, recipients of T cells from 
both WT and JAK2-/-  donors exhibited significantly less tumor mortality compared 
to those that did not receive T cells , supporting the notion that JAK2 is partially 
dispensable for T cell mediated GVL activity (Figure 1E-G).  The tumor mortality 
among recipients of JAK2-/- T cells was not significantly different (p=0.15, Log-
rank test) compared to those of WT T cells (Figure 1E-G).  These experiments 
demonstrate that JAK2 signaling in donor T cells contributes to GVHD but is 
partially dispensable for the GVL effect. 
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Figure 1. JAK2 contributes to T cell-mediated GVHD, but is dispensable for GVL. Lethally 
irradiated BALB/c (A and B) or BALB/b (C and D) mice were trans- planted with 5 × 106 TCD-BM 
alone or plus 1 × 106 (BALB/c) or 3 × 106 (BALB/b) purified T cells from WT B6 or JAK2 KO mice. 
Survival and body weight loss of BALB/c (A and B) and BALB/b recipients (C and D) are shown. 
Data shown are pooled from two to three replicate experiments with a total of 6–15 mice per group. 
Lethally irradiated BALB/c mice were transplanted with 5 × 106 TCD-BM alone or plus 2 × 103 luc-
A20 cells and either 1 × 106 purified T cells from WT or JAK2 KO mice plus 2 × 103 luc-A20 cells. 
Recipient survival (E), body weight loss (F), and tumor burden (G) are shown. Percentage survival 
and tumor mortality data shown were pooled from three replicate experiments with a total of 6–15 
mice per group. Representative BLI images were taken from one of three replicate experiments. 




IV.4.b. JAK2 inhibits Th2 and Treg polarization in vivo 
To determine how JAK2 contributes to T cell differentiation, we analyzed the 
cytokine production profile of WT and JAK2-/- T cells in allogeneic recipients 14 
days post BMT., JAK2-/- T cells had significantly less IFNγ+ Th1 differentiation in 
the spleen (Figure 2A-C).  Conversely, JAK2-/- T cells had significantly enhanced 
IL4/5+ Th2 and Foxp3+ Treg polarization (Figure 2A-C).  JAK2-/- CD8+ T cells 
also produced less IFNγ compared to WT controls (Figure 2A-C).  Though limited 
to a small positive population of cells, JAK2-/-  T cells exhibited increased IL-17+ 
Th17 differentiation (Figure 2A-C).  Similar results were observed in the liver 
(Supplemental Figure 4). 
 
Figure. 2. Donor T cells deficient for JAK2 are prone to Th2 and Treg polarization in vivo. 
Lethally irradiated BALB/c mice were transplanted with 5 × 106 Ly5.1+ TCD-BM alone or plus 1 × 
106 purified T cells (Ly5.2+) from WT B6 or JAK2 KO mice. Recipient splenic mononuclear cells 
were isolated for immunopheno- typing on day +14 post-BMT. Data depict one repre- sentative 
mouse per group for IFNγ+, IL-4/5+, IL-17+, Foxp3+ (Tregs), or IL-10+ among gated H2Kb+Ly5.1- 
CD4+ or CD8+ cells (A). Average percentages +SD (B) or absolute numbers (C) of splenic T cell 
subsets are shown from one of three replicate experiments. Splenic cells from 9 to 11 mice per 
group were ana- lyzed in total. *P < 0.05; **P < 0.01; ***P < 0.001. 
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IV.4.c. JAK2 contributes to the migratory capacity of donor T cells 
We then investigated the impact of JAK2 signaling on donor T cell migration.  
Expression of chemokine receptor, CXCR3, and the integrin, α4β7, were 
significantly decreased among CD4+ JAK2-/- T cells in the spleen of recipients 
(Figure 3A,B).  This reduction in CXCR3 expression is indicative of reduced 
trafficking among Th1 cells179, while decreased α4β7 demonstrates impaired 
migration to intestinal tissues28,180.  However, the expression of CCR6l, a key Th17 
chemokine receptor, was similar among cohorts (Figure 3A,B).  These data show 
that JAK2 activation promotes T cell homing potential to GVHD target organs.  
Consistent with the observed decrease in α4β7 expression, recipients of JAK2-/- 
T cells had significantly less tissue damage in the small and large intestine (Figure 
3C, D); a similar decrease in target organ damage was also observed in the skin 
and liver of JAK2-/- T cell recipients (Figure 3C, D).  Although these results do not 
directly assess T cell trafficking, the data suggests JAK2 contributes to the 




Figure. 3. JAK2 contributes to the migratory capacity of donor T cells. Lethally irradiated 
BALB/c mice were transplanted with 5 × 106 Ly5.1+ TCD-BM alone or plus 1 × 106 purified T 
cells (Ly5.2+) from WT B6 or JAK2 KO mice. Recipient splenic mononuclear cells were isolated 
for T cell migration surface markers on day +14 post-BMT. Flow plots show expression of 
CXCR3, CCR6, or α4β7 (A) among gated H2Kb+Ly5.1- CD4+ or CD8+ cells. (B) The mean 
frequency of T cell CXCR3, CCR6, or α4β7 expression ±SD for one of three replicate 
experiments is shown. A total of 9–11 mice per group were analyzed. (C) Quantified GVHD tissue 
damage scores ±SD from one representative experiment are shown (BMA: 6 mice; WT: 14 mice; 
JAK2 KO: 15 mice). (D) Representative H&E sections of GVHD target organs from each cohort 
showing vacuolar changes in the skin (↓); endothelialitis (#) and mononuclear infiltrates in the 
liver (*); crypt regeneration in the large intestine (LI, ^); and lamina propria inflammation in the 





IV.4.d. Pharmacologic inhibition of JAK2 with pacritinib reduces GVHD and 
spares GVL 
To translate the observations made using JAK2-/- T cells, host WT BALB/c mice 
received B6 allografts and were treated with pacritinib, a JAK2 inhibitor, or vehicle 
for 3 weeks.  Pacritinib significantly reduced acute GVHD mortality among recipient 
BALB/c mice (Figure 4A,B).  At 4 days’ post BMT, similar to results observed in 
JAK2-/- T cells, pacritinib significantly reduced CD4+ T cell production of IFNγ and 
proliferation of Th1 cells (Figure 4C). Notably, pacritinib treatment did not 
significantly impact JAK2-/- T cells in these studies, indicating the potential off 
target effects of pacritinib in this context were minimal. While ruxolitinib (JAK1/2 
inhibitor) impaired murine CTL activity against tumor in vitro (Supplemental Figure 
5), neither pacritinib nor ruxolitinib interfered with the GVL effect in vivo 
(Supplemental Figure 6A-C).  Additionally, ruxolitinib was associated with greater 
immune suppression against GVHD (p<.05, Supplemental Figure 6A-C), 
supporting that dual JAK1/2 inhibition induces broad donor T cell inactivation 
compared to pacritinib.  Pacritinib had no direct effect on P815 cells (Supplemental 
Figure 6D-F).   
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Figure 4. Pharmacological inhibition of JAK2 with pacritinib reduces GVHD and spares 
GVL. Lethally irradiated BALB/c mice were transplanted with 5 × 106 TCD- BM alone or plus 1 × 
106 T cells/mouse from WT B6 donors. Pacritinib 100 mg/kg or methylcellulose vehicle was given 
by oral gavage daily for 3 wk starting on day 0 of BMT. Recipient survival (A) and body weight 
loss (B) are shown. In separate experiments, lethally irradiated BALB/c mice were transplanted 
with carboxy- fluorescein succinimidyl ester (CFSE)-labeled T cells from either WT or JAK2 KO 
donors and treated with pacritinib or vehicle. Average percentages +SD of CFSE- diluted CD4+ 
and CD8+ T cells positive for IFNγ, IL-4/5, and IL-17 for are shown (C). A total of 12 mice/group 
were used across the three experiments (A–C). *P < 0.05; **P < 0.01; ***P < 0.001. Pac, 




IV.4.e. Pacritinib polarizes a Th2 response among DC-allostimulated, human 
T cells 
We went on to verify the immune suppressive effects of pacritinib in a human 
system.  Using cytokine- or DC-stimulated human T cells, pacritinib inhibited JAK2- 
dependent phosphorylation of STAT3 and significantly suppressed alloreactive T 
cell proliferation (Supplemental Figure 7A, B).  IL-2-mediated STAT5 signal 
transduction, required by Treg and CTL alike, was largely preserved among T cells 
exposed to pacritinib (Supplemental Figure 7A).  JAK2 inhibition of human T cells 
directed robust Th2 polarization and significantly decreased Th1 and Th17 
differentiation (Figure 5A-C).  Pacritinib also suppressed lymphocyte production of 
IL-6, IL-17A, IL-17F, and TNF-alpha181 (Supplemental Figure 7C).  As 
demonstrated in rodents168, both pacritinib and ruxolitinib reduced IFNγ-mediated 




Fig. 5. Pacritinib polarizes a Th2 response by human T cells after allogeneic stimulation in 
vitro and permits the differentiation of suppressive iTreg. Data show the effect of pacritinib 
(2.5 μM) on (A) Th1 (IFNγ) versus Th2 (IL-4), (B) T-BET expression (replicate means ± SEM, n = 
4 experiments), and (C) RORγT expression ±SD among CD4+ T cells after DC allostimulation 
(one of two experiments is shown, performed in triplicate). (D and E) iTregs were generated from 
Treg-depleted, DC-allostimulated CD4+ T cells in the presence of pacritinib (2.5 μM) or vehicle 
control. Contour plots show iTregs and corresponding Foxp3 expression. (F and G) Graphs show 
the mean frequency of iTreg and ratio of iTreg to alloreactive Tconv (CD4+, CD25+, CD127+) 
±SD after DC allostimulation. n = 6 experiments. (H) iTreg-suppressive potency is demonstrated 
against self-T cell responders stimulated by allogeneic DCs without additional drugs. One of two 
experiments are shown, each performed in triplicate. *P < 0.05; **P < 0.01.  
 
IV.4.f. Pacritinib permits the differentiation of suppressive human induced 
Treg 
CD4+ T cells were purified, depleted of natural Tregs as previously described 
(>99% non-Treg), and stimulated with allogeneic, cytokine-matured DCs for 5 days 
with pacritinib or DMSO added once on day 0.  Induced Treg (iTreg) differentiation 
was similar following DC-allostimulation, regardless of pacritinib treatment (Figure 
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5D-F).  Conversely, pacritinib significantly increased the ratio of iTreg to activated 
conventional T cells (Tconv) compared to DMSO (Figure 5G).  The suppressive 
potency of pacritinib- or DMSO-pretreated iTregs was similar, suggesting JAK2 is 
not required for human iTreg function (Figure 5H).   
 
IV.4.g. Pacritinib reduces xenograft rejection but maintains CD8+ CTL 
activity against tumor  
The immune suppressive effect of pacritinib on human T cells was tested in vivo.  
Immunodeficient NSG mice received a dorsally positioned, 1cm2, split-thickness 
human skin graft.  After a 30-day rest period, 5x106 human PBMCs, allogeneic to 
the skin donor, were injected into the mouse172,176.  Mice received pacritinib 
(100mg/kg) or vehicle twice a day by oral gavage from day 0 until day +14.  
Pacritinib significantly delayed skin graft rejection by allogeneic T cells compared 
to vehicle (Figure 6A,B).  Skin xenografts from pacritinib-treated mice therefore 
exhibited significantly less pathologic rejection at day +21 (Figure 6C,D), 
compared to the vehicle-treated controls.  IHC analysis suggested a modest 
reduction in Th1 cells (CD4+, T-BET+) in the skin of pacritinib treated mice (Figure 
6E,F).  We used an established method to generate human anti-tumor CTL in vivo 
and then test their specific killing in vitro172.  NSG mice received human PBMCs 
(30x106) and were inoculated with irradiated U937 cells (10x106) on days 0 and 
+7.  Mice were treated with pacritinib, ruxolitinib (30mg/kg twice a day, or vehicle 
as described161.  Human CD8+ T cells were isolated from the spleens of 
euthanized recipients during days +10-12 and cultured against fresh U937 target 
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cells without further drug exposure in vitro.  Ruxolitinib significantly impaired anti-
tumor activity, while CTL function was preserved among mice treated with 











Figure 6. Pacritinib reduces xenograft rejection. NSG mice received a 1-cm2 split thickness 
human skin graft. After 30 d of rest to ensure engraftment, an inoculum of 5 × 106 human PBMCs 
(allogeneic to the skin) were administered by i.p. injection. Unique pairs of donor skin and 
allogeneic PBMCs were used for each set of experiments. Pacritinib 100 mg/kg or vehicle was 
given twice a day from days 0 to +14. (A) Graph shows human skin graft survival among 
pacritinib- or vehicle-treated NSG hosts (log-rank test). (B) Representative im- ages show skin at 
time of suture removal (day −30) and at day +35. (C) His- tologic representations of the skin 
grafts uniformly harvested on day +21 demonstrate that pacritinib reduces lymphocytic infiltration 
(^) and severe basal vacuolar changes of the graft, such as the subepidermal blister (#). Low 
power at 6×, high-power Inset at 20×. (Scale bar, 400 μm.) (D) Bar graph shows pathologic skin 
graft rejection scores at day +21 among vehicle- and pacritinib- treated mice. (E and F) 
Immunohistochemistry and accompanying bar graph shows skin-resident Th1 cells at day +21 by 
dual staining of CD4 (red) and T-BET (brown). n = 2 experiments, 5–6 mice per arm. (G) Graph 
depicts mean specific lysis ±SEM by human CD8+ CTL generated in vivo using NSG mice 
transplanted with human PBMCs (30 × 106) and vaccinated with irradiated U937cells (10 × 106) 
on days 0 and +7. Mice were treated with pacritinib (100 mg/kg twice a day), ruxolitinib (30 mg/kg 
twice a day), or vehicle from day 0 up to day +12. Human CD8+ T cells were harvested from 
euthanized mice between days +10 to +12. Results shown are from one of two independent 
experiments. U937 lysis was measured by colorimetric assay after 4 h. *P < 0.05; **P < 0.01; 
****P < 0.0001. (Magnification: C and E, slides were scanned using a 20×/0.8 N.A. objective and 




While it is known that JAK2 inhibition spares Tregs and reduces Th1 
responses26,172, we demonstrate that genetic ablation of JAK2 on donor T cells or 
treatment with pacritinib significantly enhances Th2 differentiation after allo-HCT.  
Strategies to modulate Th2 over Th1 have proven effective in reducing GVHD 
lethality in rodents.  IL-18 promotes STAT6-dependent Th2 polarization, 
suppresses Th1s, and reduces GVHD yet spares GVL182.  Th2 cells are also 
required for MDSC-mediated immune suppression and GVHD prevention183.  
Additionally, the GVHD biomarker, soluble suppression of tumorigenicity 2 (sST2), 
orchestrates alloreactivity in part by binding IL-33 and preventing Th2 
differentiation184.  Therefore, we surmise that Th2 polarization contributes to the 
immune suppressive activity of JAK2 inhibition. 
 
The recipients of JAK2-/- T cells survived longer, higher body weight maintenance, 
and less GVHD pathology in their small intestine, large intestine, liver and skin 
compared to WT controls.  We also observed significantly less Th1 differentiation 
and CXCR3 expression among JAK2-/-T cells.  Further, JAK2-/- donor T cells had 
reduced expression of the α4β7 integrin that is required for gut homing by Th1 
cells.  Our data suggest targeting JAK2 may reduce GVHD in part by limiting Th1 
differentiation and the migratory capacity of alloreactive T cells28,179.  
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Species-specific immune effects were observed among the murine GVHD 
experiments compared to the human in vitro and xenogeneic tissue rejection 
experiments.  Pacritinib significantly reduced human Th17 differentiation, which is 
similar to the published results using the JAK2 inhibitor, TG10134826,172.  
Conversely, recipients of JAK2-/- T cells and those treated with pacritinib exhibited 
moderately increased Th17 cells after allo-HCT.  This is distinct from STAT3 KO 
donor T cells, which results in reduced Th17 differentiation in transplanted mice185.  
TGFβ can promiscuously activate STAT3 in T cells to facilitate murine Th17 
development186,187.  The loss of JAK2 countered by STAT3 activity via alternative 
pathways may enhance Th17 differentiation in mice but not humans due to the 
species-specific effects of TGFβ188.  This is further supported by the observation 
that JAK2-/- T cells exhibited significantly increased Treg differentiation compared 
to WT controls, which may serve as a source of TGFβ in vivo189.  Our in vitro human 
data demonstrated that JAK2 inhibition with pacritinib spared Treg differentiation, 
but did not increase the amount of Tregs compared to controls (Figure 5F).  
However, the ratio of Tregs to activated Tconv was increased with pacritinib 
(Figure 5G). 
 
An important limitation of these data is that pacritinib is a multikinase inhibitor with 
effects on pathways potentially relevant to GVHD175.  Pacritinib potently inhibits 
JAK2, FLT3, IRAK1, TNK1, ROS, and HIPK (IC50 <50nM), and also has activity 
against JAK3 and TYK2 (IC50 50-100nM) in the JAK-STAT system175.  Such 
activity by pacritinib may be important to differences seen between JAK2-/-T cells 
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and the studies using pacritinib as a JAK2 inhibitor in GVHD prevention.  However, 
the anti-JAK3 activity of pacritinib did not prevent IL-2-mediated phosphorylation 
of STAT5, which is required by Tregs and CTL.  Tyk2 and JAK2 regulate p40 
cytokine receptor signal transduction190, and Tyk2 inhibition by pacritinib might also 
impact Th1 and Th17 differentiation beyond the effects of JAK2 blockade.  
Additionally, suppression of IRAK1 and IL-1β receptor activity may modulate donor 
alloresponses191.  In comparison, ruxolitinib inhibits JAK1 and JAK2 equally161.  
Ruxolitinib is known to suppress STAT5 phosphorylation in human T cells and NK 
cells via JAK1 inhibition169,171.  Our group and others have observed that ruxolitinib, 
as opposed to pacritinib, significantly impairs human CTL function169, although this 
is not observed among murine T cells in vivo (Supplemental Figure 6A-C)168.  
These data suggest that human and mouse T cells have somewhat different 
sensitivity to Jak inhibition.  Similar to ruxolitinib, we show pacritinib also limits 
human NK cell proliferation and function in vitro (Supplemental Figure 9).  While 
pacritinib spares JAK1, we surmise its effect on NK cells is due to suppression of 
Tyk2 and impaired IL-12 activity192.  Given that pacritinib permits common gamma 
chain cytokine signal transduction, such as IL-2, its effect on JAK3 does not explain 
the drug’s inhibition of NK cells.  Our data also supports ruxolitinib induces 
profound immune suppression compared to pacritinib, yet potentially at the cost of 
CTL function required for anti-tumor activity. 
 
Our data support that neutralization or pharmacologic blockade of JAK2 with 
pacritinib preserves donor T cell mediated GVL activity.  We propose that targeting 
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JAK2, but sparing JAK1, with agents such as pacritinib is sufficient to control 
alloreactivity without impairing normal T-effector and Treg function.  A phase I/II 
acute GVHD prevention trial combining pacritinib with standard immune 
suppression after allo-HCT is actively being investigated (NCT02891603).  
Therefore, such an approach has direct translational implications in GVHD and 



















V. Conclusions and future directions 
 
Targeting p40, a shared subunit of IL-12 and IL-23 cytokines, consistently 
mitigates GVHD in clinical and preclinical studies. Our group and others have 
demonstrated that neutralization of the p40, using genetically deficient mice and 
pharmacological inhibition, alleviated acute and chronic GVHD in murine models 
through reducing Th1 and Th17 differentiation145,152. Recent data from Pidala, et 
al. demonstrates in vivo IL-12/IL-23p40 neutralization with ustekinumab blocks the 
Th1/Th17 response and improves overall survival in patients after allo-HCT150. 
Notably, in other models of autoimmunity, in which Th17 is the major mediator of 
diseases, much of the originally allocated inflammatory actions of IL-12 have since 
been shown to be influenced by IL-23, as many studies prior to IL-23 identification 
were conducted via targeting p4091,193. Regarding clinically translatable 
approaches targeting the IL-12 family, ustekinumab targets the p40 shared subunit 
between IL-23 and IL-12.  Ustekinumab added to tacrolimus and rapamycin was 
shown to be safe and effective for GVHD prophylaxis after related or unrelated 
allo-HCT.  In a randomized, blinded, placebo-controlled study, ustekinumab 
significantly improved overall survival and CRFS (Conditional Random Fields 
Score), a novel composite endpoint including moderate/severe cGVHD and 
relapse-free survival150. Guselkumab and tildrakizumab, two monoclonal 
antibodies against p19, were approved for treatment of plaque psoriasis194,195. 
However, these specific neutralizing antibodies against p19 have yet to be 
evaluated in GVHD patients. Recent findings have emphasized the need to 
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develop therapeutics methods that enable targeting of IL-12 and IL-23 signaling. 
A key point of our data is the potential involvement of IL-39. Given the novel nature 
of this cytokine, much more research is required to fully understand the role of IL-
39, especially with regards to GVT. However, our work does provide a baseline by 
which to begin evaluating whether better outcomes can be achieved by targeting 
p19 in GVHD. As mentioned above, p40 blockade has been shown to be clinically 
effective in reducing GVHD. Interestingly, we found IL-12Rβ1 to be required for 
cGVHD, consistent with our results targeting p40. Further, in the study by Pidala 
et al. in 2018, they found an overall improvement in GVHD outcomes when results 
from acute and chronic GVHD patients were combined, yet p40 blockade was 
much more effective when treating patients with cGVHD compared to acute. 
Therefore, future studies should focus on the biological differences of IL-12 and 
IL-23 in order to determine why IL-12 can exacerbate GVHD in some contexts yet 
suppress it in others, yet pharmacologically targeting p40 can be efficacious in 
reducing GVHD severity in experimental and clinical settings. 
 
Interestingly, not only do the cytokines IL-12 and IL-23 share the same cytokine 
subunit, p40, but also the cognate receptor, IL-12Rβ1. Thus, these shared motifs 
provided the rationale for blocking Th1 and Th17 responses simultaneously 
through targeting p40/IL-12Rβ1. Our data indicates that IL-39 could be responsible 
for the similar outcomes between WT and IL-12Rβ1KO observed aGVHD models. 
However, p40 itself has a diverse set of functions. Therefore, it is important to 
consider these functions as alternative explanations/ additional factors for our 
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results. For example, p40 has a chemo attractant role for macrophages mediated 
by IL-12Rβ1 alone, which is dependent on the intracellular domain of IL-12Rβ1 to 
signal; these reports were published with regard to IL-12Rβ1 signal transduction 
in response to a p40 homodimer196,197. With respect to alloreactive T cells, this p40 
homodimer was demonstrated to have antagonistic activity for CD4+ IFN 
production, yet could amplify IFN production by CD8+ T cells198. Hence, targeting 
p40 in the context of GVHD may result in enhanced Th1 responses and potentially 
hinder CD8 mediated GVT responses138.  IL-12Rβ1 promiscuity among the IL-12 
family has both assisted in the development of pharmaceuticals to target both 
pathways (as in the case of p40), yet also illuminated their complexity. Th1 and 
Th17 differentiation and stability converge at IL-12 and IL-23 signaling, 
respectively, as both signaling motifs share p40 at the cytokine level and IL-12Rβ1 
for downstream signal transmission. Supported by studies done in mice and men, 
IL-12 is documented to induce IFNγ production by Th17 cells with respect to 
cytokines in the milieu, in vivo and in vitro respectively199,200. This Th1/Th17 subset 
was shown in Crohns disease200.  
 
The use of any immunosuppressive agent carries the theoretical risk of impairing 
host defense responses to pathogens and/or decreased tumor surveillance. 
Relative risks of targeting IL-12 and/or IL-23 are well documented with respect to 
potential risk of infections. When challenged with Mycobacterium, Salmonella or 
Candida, mice lacking IL-12p35, IL-12p19 and IL-12/23p40 have phenotypes that 
generally mirror what has been observed in humans. Studies of IL-12/23p40 and 
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IL-12Rβ1 deficiencies indicate that human IL-12 and IL-23 are redundant in host 
defense to many pathogens. Importantly, allo-HCT recipients treated with 
ustekinumab did not experience any increase in opportunistic infections or 
reactivation of CMV, EBV, or HHV6 compared to the placebo arm150. One 
important factor to consider going forward is whether a similar safety profile is 
observed using p19 inhibitors. 
 
Our group has demonstrated both Th1 and Th17 subsets are required to induce 
GVHD25. Pharmacological inhibition of IL-23p19 results in reduced GVHD, and 
recent evidence suggests that IL-23R drives GVHD pathogenesis52–54,56. These 
studies show that a CD4+CD11c+IL-23R+ T cell population induces colonic 
inflammation during GVHD, indicating a key role for IL-23R expression on donor T 
cells in mediating damage to the gut after allo-HCT. Consistently, the gene 
expression levels of IL-23 and IL-23R were upregulated in murine colons after allo-
HCT54. These studies demonstrate that the colon is specifically protected via IL-
23p19 signaling blockade, and that GVL activity is maintained. In a patient cohort, 
Liu et al. observed IL-23 mRNA expressions in patients with aGVHD were 
significantly higher than those in healthy donors, and IL-23 and IL-23R expression 
were positively correlated with IL-17 expression201. These studies additionally 
showed that IL-23 serum levels were elevated during the onset of aGVHD yet 
decreased during disease remission (Table 1). In aGVHD, two out of three 
independent studies in patients found that a single nucleotide polymorphism 
(rs11209026) in IL-23R of donor origin reduced incidence of GVHD; the third study 
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did not observe any effect30,202. Hence, blocking either p19 or p40 reduces aGVHD 
and IL-23R deficiency in donor T cells results in abrogated GVHD. These results 
indicate IL-23 also plays a key role in GVHD pathogenesis. Albeit, a recent paper 
demonstrated genetic inactivation of IL-23R, or the transcription factor RORγt, 
within donor T cells similarly ablated Th17 cell formation in vivo but preserved the 
T cells' ability to induce intestinal GVHD in an indistinguishable manner compared 
to wild-type controls24. Hence, further studies are required to dissect this conflicting 
result. 
 
As with p40, IL-12Rβ1 has also been implicated to have a regulatory role, although 
there remains a lack of data in this area. IL-12Rβ1 was identified in 1994 by Chua 
et al. as a member of the hemopoietin receptor superfamily, an amino acid type I 
transmembrane protein that resembled the IL-6 signal transducer, gp130203. It was 
not until 1996 that IL-12Rβ2 was identified, which subsequently led to the 
identification of a high affinity IL-12 receptor complex when IL-12Rβ1 and IL-
12Rβ2 were coexpressed41. Notably, the existing data with respect to IL-12Rβ1 in 
murine models of GVHD is sparse, although there is an abundance regarding its 
role in conferring immunity to mycobacteria and other infections204–206 in human. 
However, given that deficiency of IL-12Rβ1 is relevant in patients, there are a 
plethora of case studies documenting related T cell responses207. The IL12Rβ1 
promoter, when deficient of the -265 to -104 region, suggested the existence of an 
important regulatory element. Furthermore, the -111A/T substitution appeared to 
cause decreased gene transcriptional activity, such that cells from -111A/A 
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individuals were observed to have increased IL12Rβ1 mRNA levels compared with 
those from -111T allele carriers. Thus, in individuals with the -111T/T genotype, 
reduced IL12Rβ1 expression may lead to augmented Th2 cytokine production in 
the skin, and subsequently contribute to the development of atopic dermatitis and 
other associated allergic diseases208.  
 
Of particular interest is the role of IL-12/IL-12Rβ1 pathway in the induction of highly 
suppressive antigen-specific Th1-like Tregs from naïve Tregs209. It was recently 
described that, in two patients with IL-12Rβ1 deficiency, features of systemic 
autoimmunity and photosensitivity were observed210. These features are similar to 
transgenic mice deficient for IL-12Rβ2, which develop an autoimmune syndrome 
consisting of anti-DNA positivity, immunocomplex glomerulonephritis, and 
multiorgan lymphoid infiltrates with features of vasculitis. However, IL-12Rβ1 
deficient patients displayed substantially less circulating memory Tfh and memory 
B cells than healthy controls85. In humans, TGF cooperates with IL-12 and IL-23 
for expression of Tfh molecules: CXCR5, ICOS, IL-21, and the transcriptional 
regulator Bcl6189. Hence, data taken from studies in IL-12Rβ1 deficient patients 
suggests a regulatory role for IL-12, perhaps derived from Treg function, which 
may explain the contradictory results observed in murine models. Albeit, the role 
of IL-12 in Tfh/B cell axis seems at baseline consistent among experimental and 
clinical studies. Our data also supports a key role for IL-12 in Tfh function, at least 
with respect to IL-21 production and BCL6 expression in cGVHD. While the 
aforementioned discrepancies are preliminary in comparison to the mass of 
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studies documenting proinflammatory roles of IL-12, there is still much to learn in 
terms of IL-12 function; especially with respect to differences versus IL-23.  
 
While promiscuity among IL-12 cytokine and/ or receptor family is a common 
theme, the degree of association with glycoprotein 130 (gp130), better known for 
its role in IL-6 signaling, has become an intriguing area of research. Gp130 forms 
the link between ‘‘IL-6R/IL-12R’’ families, which collectively include Leukemia 
Inhibitory Factor Receptor (LIF-R), IL-12Rβ1, IL-12Rβ2, Granulocyte Colony-
Stimulating Factor Receptor (GCSF-R), and Oncostatin-M Receptor (OSM-R); and 
serves as a shared signal-transducing subunit for IL-6, IL-11, Leukemia Inhibitory 
Factor (LIF), Oncostatin-M (OSM), Cilliary Neurotrophic Factor (CNTF), 
Cardiotrophin-1 (CT-1), Cardiotrophin-like cytokine (CLC), and IL-27211,212. 
Importantly, gp130 is well documented for its capacity to transduce signals, 
especially for IL-6, a staple cytokine involved in inflammation. The complex of IL-6 
and IL-6R binds to the ubiquitously expressed receptor subunit gp130, which forms 
a homodimer and thereby initiates intracellular signaling via the JAK/STAT and the 
MAPK pathways. IL-6R expressing cells can cleave the receptor protein to 
generate a soluble IL-6R (sIL-6R), which can still bind IL-6 and can associate with 
gp130 and induce signaling even on cells, which do not express IL-6R. This 
paradigm has been called IL-6 trans-signaling whereas signaling via the 
membrane bound IL-6R is referred to as classic signaling211–213. This well 
documented promiscuity is of gp130 is one of the primary reasons we 
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hypothesized that IL-23R signaling may be able to circumvent IL-12Rβ1 through 
IL-39. 
 
Other than cytokine blockade, which may target a wide variety of cell types, an 
alternative strategy to inhibit the IL-23 pathway is by targeting the receptor 
component. The crystal structure of IL-23Rα was recently reported214. Hence, 
development of pharmaceutical compounds capable of specifically binding/ 
inhibiting the IL-23R has been stagnant since its discovery in 2002. It appears that 
IL-23 binds IL-23R with an affinity of 44 nM, while binding IL-12Rβ1 with an affinity 
of 2 μM; nonetheless, the affinity of the IL-23:IL-23R complex for IL-12Rβ1 has 
been described as 25 nM, despite no apparent interaction of IL-23R with IL-12Rβ1, 
implying that there is a cooperative effect which is likely to be due to a 
conformational change of IL-23 upon binding IL-23R, which is indeed observed 
crystallographically214–218. In a recent publication, hydrogen−deuterium exchange 
mass spectrometry (HDX-MS) was used to demonstrate IL-23 binding to the N-
terminal immunoglobulin domain of IL-23R in both the solid state as well as under 
more physiologically relevant conditions. This data allowed specific identification 
of a binding epitope using a macrocyclic small molecule against IL-23R for the first 
time217. However, IL-23R antagonism is not a new concept, as a peptide antagonist 
was shown to reduce inflammation in different models of autoimmune disease219. 
The aforementioned data presents exciting new possibilities for future studies, yet 




Both IL-12R and IL-23R have been demonstrated to signal via JAK2; JAK2 
deficient donor T cells or JAK2 inhibition with pacritinib were demonstrated to 
significantly alleviate GVHD in murine models via spared Treg differentiation and 
reductions in Th1 and Th17 differentiation in in mouse and human T cells220. This 
is consistent with reports describing a common reliance on JAK2 by both IL-12 and 
IL-23. A key difference in downstream signaling is that IL-12 phosphorylates 
primarily STAT4, while IL-23 mainly induces STAT3 phosphorylation. Betts et al. 
reported that at 20 days’ post allo-HCT, pSTAT3 was significantly increased in 
CD4+ T cells among patients who would later develop aGVHD; a signaling pathway 
known to directly drive the transcription of Th17 lineage-specific genes26.  
 
JAK2 signal transduction is implicated in human autoimmune syndromes and 
GVHD.  IL-6, IL-12, and IL-23 mediate inflammation and activate T cells via 
JAK226,158–161.  Blocking the IL-6 receptor with the monoclonal antibody tocilizumab 
has demonstrated efficacy in a phase II GVHD prevention trial162.  Tocilizumab, 
however, does not fully impair pathogenic Th1/Th17 responses163, which may be 
attributed to the IL-12 and IL-23 receptor signaling-induced JAK2 activation to 
promote Th1 and Th17 differentiation, respectively. Neutralization of these p40 
cytokines prevents GVHD in murine models, and may have activity in treating 
patients with steroid refractory GVHD139. 
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JAK2 inhibition is an alternative approach to suppress IL-6 and p40 receptor signal 
transduction and induce durable tolerance to alloantigens. JAK2 inhibitors are 
clinically efficacious in myelofibrosis, a hematological disease often driven by 
constitutive JAK2 activation164.  The existing evidence regarding JAK2 as a 
therapeutic target for acute GVHD is primarily supported by observations using 
ruxolitinib, an equimolar inhibitor of JAK1 and JAK2165–168. Ruxolitinib has been 
previously demonstrated as efficacious in treating steroid refractory GVHD and is 
clearly immunosuppressive. In part, JAK1 mediates the biologic effects of common 
gamma chain cytokines, including IL-2 and IL-15. Ruxolitinib suppresses host-
reactive T cells in mice and humans. Although not observed in murine transplant 
studies, ruxolitinib treatment reduces the quantity of Tregs as well as the beneficial 
effects of NK cells in myelofibrosis patients169–171.  Therefore, a JAK2 inhibitor has 
the potential to prevent GVHD without conceding JAK1-mediated functions 
provided by donor lymphocytes. Further research determining the differential 
effects of JAK1 and JAK2 is required to resolve these conundrums.  
 
Given the recent discovery of IL-39 (p19/EBI3) and its cognate receptor (IL-
23Ra/gp130), the question pertaining to the individual requirement for each 
particular cytokine/ receptor complex becomes much more complex. IL-39R was 
shown to signal via STAT1/ STAT3 pathways, which overlaps with IL-27 and IL-23 
signaling, respectively. The manner by which IL-39R and IL-23R on T cells may 




While inhibiting JAK2 signal transduction by IL-12 and IL-23 is a promising 
strategy, the question pertaining to how the shared or disparate receptors 
contribute to signal transduction and the consequential effect on T cell 
differentiation in allo-HCT remains unclear. The advancement of targeted 
pharmacological compounds specific for IL-12 or IL-23 signaling will be required 
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